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Summary 
RNA polymerase II (Pol II) is the eukaryotic enzyme responsible for transcribing all protein-
coding genes into messenger RNA (mRNA). This thesis describes studies on the molecular 
mechanisms of Pol II translocation, -amanitin inhibition and DNA lesion recognition by Pol 
II. To study how Pol II translocates after nucleotide incorporation, we prepared elongation 
complex (EC) crystals in which pre- and post-translocation states interconvert. Crystal soak-
ing with the inhibitor -amanitin locked the EC in a new state that we identified as a translo-
cation intermediate at 3.4 Å resolution. The DNA base entering the active site occupies a 
“pre-templating” position above the central bridge helix, which is shifted and occludes the 
standard templating position. A leucine residue in the trigger loop forms a wedge next to the 
shifted bridge helix, but moves by 13 Å to close the active site for nucleotide incorporation. 
Our results support a Brownian ratchet mechanism of elongation that involves swinging of 
the trigger loop between open, wedged, and closed positions, and suggest that -amanitin 
impairs nucleotide incorporation and translocation by trapping the trigger loop and bridge 
helix in a translocation intermediate. Cells use transcription-coupled repair (TCR) to effi-
ciently eliminate DNA lesions such as UV-induced cyclobutane pyrimidine dimers (CPDs). 
Here we present the structure-based mechanism for the first step in eukaryotic TCR, CPD-
induced stalling of Pol II. A CPD in the transcribed strand slowly passes a translocation 
barrier, and enters the polymerase active site. The CPD 5’-thymine then directs uridine mo-
nophosphate (UMP) misincorporation into mRNA, which blocks translocation. Artificial re-
placement of the UMP by adenosine monophosphate (AMP) enables CPD bypass, thus Pol 
II stalling requires CPD-directed misincorporation. In the stalled complex, the lesion is inac-
cessible, and the polymerase conformation is unchanged. This is consistent with non-
allosteric recruitment of repair factors and excision of a lesion-containing DNA fragment in 
the presence of Pol II. CPD recognition is compared with the recognition of a cisplatin-
induced guanine-guanine intrastrand crosslink. Similarities and differences in the detailed 
mechanism of transcriptional stalling at the two different dinucleotide lesions are discussed. 
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1 Introduction 1
1 Introduction 
1.1 The flow of genetic information 
The genetic information in a cell is stored in the form of deoxyribonucleic acid (DNA). In order 
to make use of the information, DNA is transcribed into ribonucleic acid (RNA) by DNA-
dependent RNA polymerases. RNA molecules, in turn, are translated into protein by the 
ribosome. The directional flow of genetic information from DNA via RNA to protein was put 
forward as "The Central Dogma of molecular biology" by Francis Crick in 1958 (Crick, 1970; 
Thieffry & Sarkar, 1998) (Figure 1). 
 
 
Figure 1: The central dogma of molecular biology 
1.2 DNA-dependent RNA polymerases 
The existence of cellular DNA-dependent RNA polymerases (RNAPs) was first demonstrated 
independently by Jerard Hurwitz (Hurwitz et al, 1960) and Samuel Weiss (Weiss & Naka-
moto, 1961). Whereas in prokaryotes there is only one RNAP, in eukaryotes different kinds 
of RNA molecules are synthesized by at least three distinct RNAPs, discovered by the end of 
the 1960s (Roeder & Rutter, 1969). In plants a fourth type of RNAP was recently discovered 
(Herr et al, 2005; Kanno et al, 2005). Eukaryotic RNA polymerase (Pol) I is located in the 
nucleoli and produces 5.8S, 18S and 28S ribosomal RNAs (rRNA). Pol II is located in the 
nucleoplasm and produces messenger RNAs (mRNA) from all protein-coding genes, small 
nucleolar RNAs (snoRNAs) and some small nuclear RNAs (snRNAs). Pol III is also located 
in the nucleoplasm and produces transfer RNAs (tRNA), 5S rRNA, some snRNAs and other 
small RNAs (Alberts, 2002; Berg, 2001). Pol IV is thought to play a role in the silencing of 
repetitive DNA sequences in plants by RNA-directed DNA methylation (Till & Ladurner, 
2007). 
The eukaryotic RNA polymerases also differ in their sensitivity to the inhibitor -amanitin, a 
deadly mushroom toxin from Amanita phalloides (death cap) (Schwartz et al, 1974). Pol I is 
insensitive to the toxin, Pol III is only inhibited by higher concentration of -amanitin (Ki = 10-
40 μM), and Pol II is most sensitive (Ki = 3 nM) (Wieland & Faulstich, 1991). 
1 Introduction 2
1.3 The mRNA transcription cycle 
The regulation of gene transcription is one of the most important steps for the control of cell 
growth, cell differentiation and the proper response to environmental signals. Defects in 
transcription regulation can be the cause for severe diseases like cancer. 
 
Figure 2: The transcription cycle. Adapted from (Svejstrup, 2004). 
The transcription of a gene is characterized by a cycle of events, named "the transcription 
cycle" (Figure 2). The mRNA transcription cycle is most complex, and it involves a plethora of 
factors in addition to Pol II, many of which are important for gene regulation (Figure 3, Table 
1) (Hahn, 2004; Svejstrup, 2004). The mRNA transcription cycle can be roughly divided into 
three stages: initiation, elongation and termination. Most of the regulation takes place during 
the initiation phase. The chromatin at the promoter region must be modified appropriately to 
allow initiation (Li et al, 2007). Pol II then assembles at the core promoter together with sev-
eral general transcription factors (GTFs) and coactivators (see Table 1) to form the pre-
initiation complex (PIC) (Bushnell et al, 2004; Chen et al, 2007; Hahn, 2004; Miller & Hahn, 
2006). Additional regulatory factors, namely activators and repressors bind to enhancer and 
silencer elements on the DNA respectively, and transmit regulatory signals via the coactiva-
tors. In the PIC the double-stranded promoter DNA must be melted to make the template 
DNA accessible for the polymerase. This results is the formation of a transcription bubble, 
i.e. the open complex. Pol II can then initiate template DNA-dependent mRNA synthesis. Pol 
II leaves most of the initiation factors behind at the promoter (promoter clearance) to enter 
into elongation phase. These factors (scaffold complex) greatly supports re-initiation by 
another Pol II molecule (Hahn, 2004). During the elongation phase the mRNA is produced in 
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a processive manner. The pre-mRNA is synthesized by Pol II and co-transcriptionally proc-
essed by capping and splicing. Besides the factors required for these processes, elongation 
factors are involved, which modulate the catalytic activity of Pol II, pausing of Pol II, and 
transcriptional arrest (TFIIS) (Sims et al, 2004). Additional factors are required to allow tran-
scription through chromatin (Armstrong, 2007; Kulaeva et al, 2007; Li et al, 2007). Termina-
tion occurs at the end of a gene (Gilmour & Fan, 2008). The RNA is cleaved and 
polyadenylated upon a signal on the transcript. Pol II is then removed from the DNA and 
recycled to enter another round of transcription. The C-terminal domain of the largest subunit 
of Pol II (CTD) couples mRNA transcription to the subsequent events of mRNA biogenesis, 
namely co-transcriptional mRNA processing, chromatin remodeling and modification, DNA 
repair, mRNA packaging, RNA editing and nuclear mRNA export (for reviews see 
(Buratowski, 2003; Hirose & Manley, 2000; Meinhart et al, 2005)). It does so by recruiting 
factors, which recognize the phosphorylation pattern of the CTD, which changes during the 
transcription cycle in a specific manner. 
 
Figure 3: The pathway of transcription initiation and reinitiation for Pol II. 
See Table 1 for a description of each transcription factor and Mediator (Med). Adapted from (Hahn, 2004). 
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Table 1: Saccharomyces cerevisiae Pol II general transcription factors and coactivators 
Factor 
 
 number of 
subunits 
Function (Hahn, 2004) 
TFIIA  2 Stabilizes TBP and TFIID-DNA binding. Blocks transcription inhibitors. Positive and 
negative gene regulation. 
TFIIB  1 Binds TBP, Pol II and promoter DNA. Helps fix transcription start site. 
TFIID TBP 1 Binds TATA element and deforms promoter DNA. Platform for assembly of TFIIB, 
TFIIA and TAFs. 
 TAFS 14 Binds INR and DPE promoter elements. Target of regulatory factors. 
Mediator  24 Binds cooperatively with Pol II. Kinase and acetyltransferase activity. Stimulates basal 
and activated transcription. Target of regulatory factors. 
TFIIF  3 Binds Pol II and is involved in Pol II recruitment to PIC and in open complex formation. 
TFIIE  2 Binds promoter near transcription start. May help open or stabilize the transcription 
bubble in the open complex. 
TFIIH  10 Functions in transcription and DNA repair. Kinase and two helicase activities. Essential 
for open complex formation. Mutations in IIH can cause human disease. 
1.4 Composition and structure of RNA polymerases 
DNA-dependent RNA polymerases can be classified into two families, comprising single 
subunit and multisubunit RNA polymerases, respectively (Cramer, 2002a). 
The single subunit family encompasses RNA polymerases of bacteriophages (e.g. T7, T3, 
SP6) and mitochondrial RNA polymerase. The respective enzymes all consist of a single 
protein subunit, characterized by a right hand-like architecture with palm, thumb and finger 
domains (canonical domains), similar to DNA polymerases. The best studied single subunit 
RNA polymerase is from the bacteriophage T7. It consists of 883 residues (99 kDa) and the 
crystal structure of the free enzyme was reported already in 1993 (Sousa et al, 1993). 
The multisubunit RNA polymerase family includes the RNA polymerases from all three do-
mains of life, bacteria, archaea and eukaryotes (Cramer, 2002a). Whereas bacteria and 
archaea possess only one type of RNA polymerase, all eukaryotes have the nuclear Pol I, II, 
and III. Plants possess additional multisubunit RNAPs, Pol IV and the RNAP of chloroplasts. 
There is no sequence or structural homology between single and multisubunit RNAPs de-
tectable. Therefore the existence of common topological features and mechanistic principles 
could be the result of convergent evolution (Cramer, 2002a). Multisubunit RNAPs contain 
between five and 17 protein subunits and have total molecular weights between around 400 
to around 700 kDa (Table 2). Five core subunits of multisubunit RNAPs are conserved be-
tween all three kingdoms of life and result in a similar general architecture of the enzymes 
(Cramer, 2002b). The overall structure is reminiscent of a crab claw with a large central cleft. 
The active center is located at the floor of the cleft, and it's high structural conservation sug-
gests a general catalytic mechanism for all multisubunit RNAPs. The additional subunits lie 
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on the outside of the five-subunit core enzyme and thereby change the interaction surface of 
the RNAPs. Thus the additional subunits probably fulfill the domain-specific needs for 
transcription regulation by factors interacting with the RNAPs. 
Crystal structures have been determined of bacterial RNA polymerases (Thermus aquaticus, 
Thermus thermophilus) (Vassylyev et al, 2002; Zhang et al, 1999), archaeal RNA polym-
erase (Sulfolobus solfataricus) (Hirata et al, 2008) and eukaryotic Pol II (Saccharomyces 
cerevisiae) in it's 10-subunit form (Cramer et al, 2000; Cramer et al, 2001) and 12-subunit 
form (Armache et al, 2003; Armache et al, 2005; Bushnell & Kornberg, 2003). For the Pol I 
and Pol III enzymes crystal structures are still lacking, however electron microscopic struc-
tures have been published at 12 and 17 Å, respectively (Fernandez-Tornero et al, 2007; 
Kuhn et al, 2007). 
Table 2: Subunit composition of multisubunit RNA polymerases 
RNA polymerase Pol I Pol II Pol III Archaea Bacteria 
Ten-subunit core A190 Rpb1 C160 A' + A'' ' 
 A135 Rpb2 C128 B (B' + B'')  
 AC40 Rpb3 AC40 D  
 AC19 Rpb11 AC19 L  
 Rpb6 (ABC23) Rpb6 Rpb6 K  
 Rpb5 (ABC27) Rpb5 Rpb5 H - 
 Rpb8 (ABC14.5) Rpb8 Rpb8 - - 
 Rpb10 (ABC10 ) Rpb10 Rpb10 N - 
 Rpb12 (ABC10 ) Rpb12 Rpb12 P - 
 A12.2 Rpb9 C11 - - 
Stalk A14 Rpb4 C17 F - 
 A43 Rpb7 C25 E' - 
A49 (Tfg1/Rap74) C37 - - TFIIF-like 
subcomplex
a
 
A34.5 (Tfg2/Rap30) C53 - - 
- - C82 - - 
- - C34 - - 
Pol III-specific 
subcomplex 
- - C31 - - 
Number of 
subunits 
14 12 17 11 (12) 5 
Molecular weight 
in kDa (species) 
589 (S. cerevisiae) 514 (S. cerevisiae) 693 (S. cerevisiae) 380 (P. furiosus) 375 (T. aquaticus) 
a
The two subunits in Pol I and Pol III are predicted to form heterodimers that resemble part of the Pol II initiation/elongation 
factor TFIIF, which is composed of subunits Tfg1, Tfg2, and Tfg3 in Saccharomyces cerevisiae, and of subunits Rap74 and 
Rap30 in human. 
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Figure 4: Structure of complete 12-subunit RNA polymerase II elongation complex (Kettenberger et al, 
2004). 
Two views of a ribbon model of the protein subunits and nucleic acids, side view (left) and top view (right). The 
polymerase subunits Rpb1–Rpb12 are colored according to the key between the views. Template DNA, 
nontemplate DNA, and product RNA are shown in blue, cyan, and red, respectively. Phosphorous atoms are 
indicated as spheres and extrapolated B-form downstream DNA is colored in light pink. Eight zinc ions and the 
active site magnesium ion are depicted as cyan spheres and a magenta sphere, respectively. This color code is 
used throughout. Secondary structure assignments for pol II are according to (Cramer et al, 2001) and (Armache 
et al, 2005). This figure is adapted from (Kettenberger et al, 2004). 
1.5 Structure of RNA polymerase II 
Pol II consists of a 10-subunit core enzyme and a peripheral heterodimer of subunits Rpb4 
and Rpb7 (stalk, Table 2, Figure 4). The core enzyme comprises subunits Rpb1, Rpb2, 
Rpb3, and Rpb11, which contain regions of sequence and structural similarity in Pol I, Pol III, 
bacterial RNA polymerases (Vassylyev et al, 2002; Zhang et al, 1999), and the archaeal 
RNA polymerase (Kusser et al, 2008; Murakami, 2007). The Pol II core also comprises 
subunits Rpb5, Rpb6, Rpb8, Rpb10, and Rpb12, which are shared between Pol I, II, and III 
(common subunits, Table 2). Counterparts of these common subunits except Rpb8 exist in 
the archaeal polymerase, but only a counterpart of Rpb6 exists in the bacterial enzyme 
(Minakhin et al, 2001). Finally, homologues of the core subunit Rpb9 exist in Pol I and Pol III, 
but not in the archaeal or bacterial enzyme. Initial electron microscopic studies of Pol II re-
vealed the overall shape of the enzyme (Darst et al, 1991). The core Pol II could subse-
quently be crystallized, leading to an electron density map at 6 Å resolution (Fu et al, 1999). 
Crystal improvement by controlled shrinkage and phasing at 3 Å resolution resulted in a 
backbone model of the Pol II core (Cramer et al, 2000). This revealed that Rpb1 and Rpb2 
form opposite sides of a positively charged active center cleft, whereas the smaller subunits 
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are arrayed around the periphery. Refined atomic structures of the core Pol II at 3.1 and 2.8 
Å resolution were obtained in two different conformations and revealed domain-like regions 
within the subunits, as well as surface elements predicted to have functional roles (Cramer et 
al, 2001) (Figure 4 Figure 5). The active site and the bridge helix, which spans the cleft, line 
a pore in the floor of the cleft. The Rpb1 side of the cleft forms a mobile clamp, which was 
trapped in two different open states in the free core structures (Cramer et al, 2001) but was 
closed in the structure of a core complex that included DNA and RNA (Gnatt et al, 2001). 
The mobile clamp is connected to the body of the polymerase by five switch regions that 
show conformational variability. The Rpb2 side of the cleft consists of the lobe and protrusion 
domains. Rpb2 also forms a protein wall that blocks the end of the cleft. The Pol II core 
structures lacked subunits Rpb4 and Rpb7, which can dissociate from the yeast enzyme 
(Edwards et al, 1991). Crystallographic backbone models of the complete 12-subunit Pol II at 
4 Å resolution revealed the exact position and orientation of Rpb4/7 and showed that it 
formed a wedge between the clamp and the linker to the unique tail-like C-terminal repeat 
domain (CTD) of the polymerase (Armache et al, 2003; Bushnell & Kornberg, 2003). In all 
crystal structures of the complete Pol II the clamp was observed in a closed conformation. 
The crystal structure of free Rpb4/7 together with an improved resolution of the complete Pol 
II crystals finally enabled refinement of a complete atomic model of Pol II (Armache et al, 
2005). The CTD of Pol II (see chapter 1.3) is flexibly linked to the core enzyme and consists 
of heptapeptide repeats of the consensus sequence YSPTSPS. It is disordered in crystal 
structures of Pol II.  
1.6 The RNA polymerase II elongation complex and nucleotide 
incorporation 
During the elongation phase of transcription, the polymerases move along a DNA template 
and synthesize a complementary chain of ribonucleotides. The events required for the addi-
tion of each nucleotide to the product RNA form a cyclic process, referred to as the "Nucleo-
tide Addition Cycle" (NAC). RNA extension begins with binding of a nucleoside triphosphate 
(NTP) substrate to the transcription elongation complex (EC) that is formed by the polym-
erase, DNA, and RNA. Catalytic addition of the nucleotide to the growing RNA 3' end then 
releases a pyrophosphate ion. Finally, translocation of DNA and RNA frees the substrate site 
for binding of the next NTP. The EC is characterized by an unwound DNA region, the tran-
scription bubble. The bubble contains a short hybrid duplex formed between the DNA tem-
plate strand and the RNA product emerging from the active site. The mechanism of RNA 
elongation was elucidated by structural studies of Pol II-nucleic acid complexes (elongation 
complexes, Figure 4, Figure 5). EM first revealed the point of DNA entry to the Pol II cleft 
(Poglitsch et al, 1999). The first crystal structure of a Pol II-nucleic acid complex was that of 
the core Pol II transcribing a tailed template DNA (Gnatt et al, 2001), which allows for pro-
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moter-independent transcription initiation. This structure revealed downstream DNA entering 
the cleft and a 8 to 9 base pair DNA-RNA hybrid in the active center. Comparison with the 
high-resolution core Pol II structure (Cramer et al, 2001) revealed protein surface elements 
predicted to play functional roles. Later, polymerase EC structures utilized different kinds of 
synthetic DNA-RNA scaffolds. A mismatch bubble scaffold contained upstream and down-
stream DNA duplex with RNA annealed to a central mismatched bubble region (Kettenberger 
et al, 2004) (Figure 4). The upstream DNA duplex and the nontemplate strand in the bubble 
region were however disordered in the crystal structure. Reduced scaffolds, lacking those 
disordered parts ("minimal nucleic acid scaffolds", first used in (Westover et al, 2004a)) or 
lacking the entire nontemplate strand (Westover et al, 2004b) were applied. The synthetic 
scaffold EC structures revealed the exact location of the downstream DNA and several nu-
cleotides upstream of the hybrid. Mechanisms were suggested for how Pol II unwinds down-
stream DNA and how it separates the RNA product from the DNA template at the end of the 
hybrid. Additional structures of Pol II ECs included the NTP substrate (Kettenberger et al, 
2004; Wang et al, 2006; Westover et al, 2004a). These studies suggested how the polym-
erase selects the correct NTP and how it incorporates a nucleotide into RNA. The NTP was 
crystallographically trapped in the insertion site (Wang et al, 2006; Westover et al, 2004a), 
which is apparently occupied during catalysis, but also in an overlapping, slightly different 
location, suggesting an inactive NTP-bound preinsertion state of the enzyme (Kettenberger 
et al, 2004). The NTPs in both states form Watson-Crick interactions with a base in the DNA 
template strand. Binding of the NTP to the insertion site involves folding of the trigger loop 
(Wang et al, 2006), a mobile part of the active center first observed in free bacterial RNA 
polymerase (Vassylyev et al, 2002), and in the Pol II-TFIIS complex (Kettenberger et al, 
2003). Folding of the trigger loop closes the active site and may be involved in selection of 
the correct NTP. The NTP complex structures revealed contacts of the nucleotide with the 
polymerase, which explain discrimination of ribonucleotides against deoxyribonucleotides, 
and provided insights into the selection of the nucleotide complementary to the templating 
DNA base. Catalytic nucleotide incorporation apparently follows a two-metal ion mechanism 
suggested for all polymerases (Steitz, 1998). The Pol II active site contains a persistently 
bound metal ion (metal A) and a second, mobile metal ion (metal B) (Cramer et al, 2001). 
Metal A is held by three invariant aspartate side chains and binds the RNA 3' end (Cramer et 
al, 2001), whereas metal B binds the NTP triphosphate moiety (Westover et al, 2004a). 
Recent studies of functional complexes of the bacterial RNA polymerase revealed the close 
conservation of the EC structure (Vassylyev et al, 2007a) and provided additional insights 
into nucleotide incorporation (Vassylyev et al, 2007b). As for Pol II, NTP binding to the inser-
tion site can induce folding of the trigger loop. However, in the presence of the antibiotic 
streptolydigin the NTP binds in the inactive, preinsertion state, in which the triphosphate and 
metal B are too far from metal A to permit catalysis. This finding supported a two-step 
mechanism of nucleotide incorporation (Kettenberger et al, 2004; Vassylyev et al, 2007b). 
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The NTP would first bind in the inactive state to an open active center conformation. Com-
plete folding of the trigger loop then leads to closure of the active center, delivery of the NTP 
to the insertion site, and catalysis. An alternative model for nucleotide addition involves bind-
ing of the NTP to a putative entry site in the pore, in which the nucleotide base is oriented 
away from the DNA template, and rotation of the NTP around metal ion B directly into the 
insertion site (Westover et al, 2004a). 
 
Figure 5: Structure of the Pol II elongation complex 
(A) Overview of the EC structure (Kettenberger et al, 2004). The view is as in Figure 4, left. 
(B) Superposition of NTP-binding sites [red, insertion site (Wang et al, 2006; Westover et al, 2004a); violet, entry 
site (Westover et al, 2004a); pink, inactive preinsertion-like state (Kettenberger et al, 2004). 
(C) Functional Pol II surface elements in the EC. 
The EC of the single subunit T7 RNAP has been studied in great detail (Steitz, 2004; Steitz, 
2006; Temiakov et al, 2004). Several important intermediates of the nucleotide addition cycle 
could be isolated and crystallographically analyzed at high resolution, resulting in a rather 
detailed mechanistic understanding of elongation in this system. Despite the structural differ-
ences between T7 RNAP and multisubunit RNAPs, there are remarkable similarities in some 
aspects of the elongation mechanism, including the course of nucleic acids through the 
active center, the two-metal ion catalytic mechanism, binding of the template-product helix 
from the minor groove side, passing of the transcript through an exit tunnel, and stacking of 
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an -helix against the growing end of the template-product duplex (Cramer, 2002a; Steitz, 
2006). 
1.7 Obstacles during elongation 
During active transcription, Pol II must overcome intrinsic DNA arrest sites, which are gener-
ally rich in A-T base pairs and pose a natural obstacle to transcription. At such sites, Pol II 
moves backward along DNA and RNA, resulting in extrusion of the RNA 3' end through the 
polymerase pore beneath the active site and transcriptional arrest. The RNA cleavage stimu-
latory factor TFIIS can rescue an arrested polymerase by creating a new RNA 3' end at the 
active site from which transcription can resume. The mechanism of TFIIS function was eluci-
dated with the structures of Pol II and a Pol II EC in complex with TFIIS (Kettenberger et al, 
2003; Kettenberger et al, 2004). TFIIS inserts a hairpin into the polymerase pore and com-
plements the active site with acidic residues, changes the enzyme conformation, and reposi-
tions the RNA transcript (Kettenberger et al, 2003; Kettenberger et al, 2004). These studies 
supported the idea that the Pol II active site is tunable, as it can catalyze different reactions, 
including RNA synthesis and RNA cleavage (Kettenberger et al, 2003; Sosunov et al, 2003). 
Other obstacles to transcription are bulky lesions in the DNA template strand, e.g. the UV-
light induced cyclobutane pyrimidine dimer (CPD) or intrastrand cross-links induced by the 
anticancer drug cisplatin. Bulky DNA lesions can block transcription and replication, and lead 
to mutations during replication, causing cancer (Mitchell et al, 2003). Cells can eliminate 
bulky DNA lesions slowly by genome-wide nucleotide excision repair (NER). However, for 
rapid and efficient repair cells use a NER sub-pathway referred to as transcription-coupled 
DNA repair (TCR). TCR specifically removes lesions such as CPDs from the DNA strand 
transcribed by Pol II (Saxowsky & Doetsch, 2006). It is thought that only those lesions that 
can stably stall Pol II trigger TCR. CPDs are bulky lesions that lead to Pol II stalling, but other 
types of damages, such as oxidative damages, can be bypassed by Pol II, and would escape 
TCR (Charlet-Berguerand et al, 2006). Pol II stalling apparently triggers TCR by recruitment 
of a transcription-repair coupling factor (Rad26/CSB in yeast/human), and factors required 
for subsequent steps of nucleotide excision repair, including TFIIH, which unwinds DNA, and 
endonucleases, which incise the DNA strand on either side of the lesion (Mu & Sancar, 1997; 
Saxowsky & Doetsch, 2006; Selby et al, 1997; Svejstrup, 2002; Tremeau-Bravard et al, 
2004). The obtained DNA gap is subsequently filled by DNA synthesis and ligation (Prakash 
& Prakash, 2000; Sancar, 1996). 
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1.8 Open questions and scope of this work 
The structures of the Pol II elongation complexes together with numerous functional studies 
have given spectacular insights into the mechanism of mRNA transcription. Structural and 
functional studies of bacterial and T7 RNA polymerase elongation complexes allow for inter-
esting comparisons. However, many aspects of the Pol II transcription mechanism require 
further investigation, some of which have been studied in this work. 
Among the unresolved issues was the molecular mechanism of translocation of Pol along the 
template DNA after nucleotide incorporation. Therefore, the aim of this work was the isolation 
and structural characterization of Pol II EC states, informative on the mechanism of translo-
cation. In particular, an intermediate of translocation was sought. In this context, also the 
mechanism of inhibition by the mushroom toxin -amanitin, a proposed translocation inhibi-
tor, was further examined. This part of the work is described in chapter 2. 
In addition, the mechanism of recognition of bulky DNA lesions such as UV- and cisplatin-
induced lesions by transcribing Pol II was unknown. To address this question, such lesions 
were introduced into the DNA template strand at several different positions around the po-
lymerase active site and the resulting Pol II ECs were studied structurally and in RNA elon-
gation assays. This part of the work is described in chapter 3. The analysis concerning the 
cisplatin lesion was mainly conducted by Gerke Damsma (Damsma et al, 2007). 
All crystal structures of Pol II ECs are limited to moderate resolution (  3.5-4 Å). Higher 
resolution would allow more detailed insight into many mechanistic aspects. Attempts to 
improve the resolution of Pol II EC diffraction data are summarized in chapter 5.2. 
Unpublished structures of Pol II ECs with various nucleic acid scaffold, which have been 
obtained during the time of this thesis work, are listed in chapter 5.1. They may be a refer-
ence for future experimental design or published in the context of future research projects. 
1.9 Additional contributions 
This chapter lists additional contributions, which are not described in this thesis. 
Several open questions on the architecture of the Pol II EC remained. Although an RNA 20-
mer was used in the assembly of the complete Pol II EC, electron density was only observed 
for ten nucleotides from the 3'-end (Kettenberger et al, 2004). The part of the RNA further 
beyond the DNA-RNA hybrid was obviously mobile or disordered in this complex. Exploring 
the path of the RNA exiting Pol II was addressed in collaboration with the group of Jens 
Michaelis. Single molecule fluorescence resonance energy transfer (FRET) experiments 
were developed and applied in this lab. This work has been published (Andrecka et al, 2008). 
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Another open question on the EC architecture concerned the exact dimensions of the tran-
scription bubble in a natural EC. Ultimate clarification of this issue by existing Pol II EC struc-
tures was precluded by the design of the nucleic acid scaffolds, containing mismatches or 
lacking the respective portion (Kettenberger et al, 2004; Westover et al, 2004a; Westover et 
al, 2004b). The question of the exact location of downstream bubble opening was addressed 
in collaboration with the group of Dmitry Temiakov, who applied fluorescence quenching 
experiments. This study is published (Kashkina et al, 2007).  
Although Pol II generally uses DNA as a template, there was also evidence that Pol II can 
use RNA templates. Synthetic RNA scaffolds were used to investigate the RNA-dependent 
RNA synthesis activity in vitro and structurally. These experiments were mainly conducted by 
Elisabeth Lehmann, and the results are published (Lehmann et al, 2007). 
The inhibition of Pol II transcription initiation by RNA molecules had been described in the 
literature. The complex of Pol II with an in-vitro selected inhibitory RNA molecule (aptamer) 
was examined using x-ray crystallography and binding assays mainly by Hubert Ketten-
berger in collaboration with the group of Michael Famulok. A natural RNA inhibitor from Mus 
musculus - the B2 RNA – was prepared and used in competition assays with the RNA ap-
tamer. The attempts to obtain structural information on the inhibition mechanism by a natural 
RNA inhibitor were so far unsuccessful (Lehmann, 2006). Parts of the work on the RNA 
inhibitors have been published (Kettenberger et al, 2006). 
The fidelity determinants of Pol II transcription are far less investigated than that of DNA 
replication. Template misalignment, an interesting mechanism affecting transcription fidelity, 
was examined in collaboration with the group of Dmitry Temiakov. This study has been pub-
lished (Kashkina et al, 2006). 
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2 Molecular basis of RNA polymerase II translocation and 
-amanitin inhibition 
2.1 Introduction 
The nucleotide addition cycle (NAC) of transcription begins with binding of a nucleoside 
triphosphate (NTP) substrate to the RNA polymerase (Pol) II elongation complex (EC). The 
EC then incorporates a nucleotide into the growing RNA, generating a pyrophosphate ion, 
and leading to the pre-translocation state. The polymerase subsequently translocates down-
stream along DNA and RNA, to generate the post-translocation state and a free substrate-
binding site for the next NTP, completing the NAC. X-ray crystallography of Pol II ECs re-
vealed how Pol II binds to DNA and RNA in the pre- (Gnatt et al, 2001) and post-
translocation states (Kettenberger et al, 2004; Westover et al, 2004a), and how it binds NTP 
in various ways (Kettenberger et al, 2004; Wang et al, 2006; Westover et al, 2004a). 
Despite this progress, the structural basis for translocation remains poorly understood. A 
comparison of the free crystal structures of core Pol II and a bacterial RNA polymerase ini-
tially suggested that translocation involves a conformational change in the highly conserved 
bridge helix within the active center (Cramer et al, 2001; Gnatt et al, 2001). The bridge helix 
was straight in Pol II (Cramer et al, 2001), but was bent and partially unwound at its center in 
the bacterial RNA polymerase (Zhang et al, 1999). The straight bridge helix stacked onto the 
end of the pre-translocated DNA-RNA hybrid, and its possible bending towards the hybrid 
was suggested to accompany nucleic acid movement during translocation (Cramer et al, 
2001; Gnatt et al, 2001). In a subsequent structure of another bacterial RNA polymerase, the 
central region of the bridge helix was flipped-out and contacted the adjacent, previously 
mobile trigger loop, which was suggested to influence bridge helix movement (Vassylyev et 
al, 2002). Biochemical studies of bacterial RNA polymerases revealed the functional coop-
eration of the bridge helix and trigger loop, and suggested more detailed models of transloca-
tion (Bar-Nahum et al, 2005; Epshtein et al, 2002). Alternative bridge helix conformations 
were also observed within the same RNA polymerase, supporting the functional relevance of 
bridge helix movement (Tuske et al, 2005). 
The mushroom toxin -amanitin was suggested to interfere with bridge helix movement 
during translocation since it binds the free Pol II core below the bridge helix (Bushnell et al, 
2002). Kinetic data supported the idea that -amanitin inhibits translocation (Gong et al, 
2004). However, a difficulty with this model was that -amanitin bound only one residue in 
the bridge helix, and that this residue was separated by one turn from the residues that ap-
parently change conformation. An alternative model for inhibition suggested that -amanitin 
interferes with movement of the trigger loop, which closes over the active site during nucleo-
tide incorporation (Wang et al, 2006). 
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To investigate structurally how Pol II translocation occurs, and how -amanitin interferes with 
it, we formed crystals of the complete Pol II EC in which the pre- and post-translocation 
states co-exist. Soaking the inhibitor into such a crystal resulted in the structure of the -
amanitin-inhibited Pol II EC. This structure showed that -amanitin traps the trigger loop in a 
new conformation, and stabilizes the EC in a previously unobserved state that corresponds 
to a translocation intermediate. The new structure leads to an extended model for the NAC 
and suggests how -amanitin interferes with both nucleotide incorporation and Pol II translo-
cation. 
2.2 Results 
2.2.1 Co-existence of pre- and post-translocation states in Pol II EC 
crystals 
Previous structures of the Pol II EC were not informative on the mechanism of translocation 
since they always revealed the same polymerase conformation, although the nucleic acids 
adopted either the pre- or the post-translocation conformation. Since the EC is thought to 
exist in an equilibrium of pre- and post-translocation states in solution, we sought crystals of 
the complete Pol II EC that preserve this equilibrium. To detect the translocation state of 
nucleic acids within EC crystals, we labeled the DNA template strand in the hybrid with 5-
bromouracil, and determined the bromine position by anomalous diffraction. With the use of a 
minimal synthetic nucleic acid scaffold (Figure 6A) and at low magnesium ion concentration, 
two bromine peaks were observed, one at position -4, indicating the post-translocation state, 
and one at position -3, corresponding to the pre-translocation state (Figure 6C, Table 3, 
chapter 2.4) (position +1 denotes the nucleotide incorporation site, and positive and negative 
numbers denote downstream and upstream positions, respectively). This indicates that Pol II 
binds the hybrid in a defined, one base pair register, consistent with movement of Pol II in 
discrete one base pair steps (Abbondanzieri et al, 2005). Furthermore, both translocation 
states co-existed within these crystals. Since nucleic acids were not fixed by crystal contacts, 
we assumed that the two states inter-convert in each EC of the crystal. The EC preparation 
used for crystallization was functional, as it supported RNA elongation, and was also sensi-
tive to -amanitin inhibition (Figure 6B). 
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Figure 6: Structure of the -amanitin-inhibited Pol II elongation complex (EC) 
(A) Pre- and post-translocation states of the EC. The nucleic acid scaffold used in this study is depicted sche-
matically with respect to the active site metal ion A (magenta). The color key is used throughout. 
(B) Nucleotide incorporation and inhibition of the EC by -amanitin. Inhibition of the EC was tested with a tran-
script extension assay (chapter 2.4.4). In the presence of -amanitin and 10 μM GTP, incorporation of the next 
complementary nucleotide was inhibited (lane 2). At higher substrate concentration (100 μM), slow incorporation 
of one (lanes 3-8), or two nucleotides (lanes 9-14) is possible in the presence of -amanitin. 
(C-D) Bromine anomalous difference Fourier maps (pink net) of the free EC (C) and the -amanitin-inhibited EC 
(D). The maps were calculated with phases from the Pol II model after molecular replacement and rigid body 
refinement and contoured at 4.4  . The final model of the nucleic acids and metal A in the -amanitin-inhibited 
EC is superimposed. In the absence of -amanitin, two peaks were observed, coinciding with the locations of the 
bromine atom (yellow sphere) in a 5-bromouracil residue at positions -3 and -4 in the template strand (Table 3). In 
the presence of -amanitin, one peak was observed, coinciding with the location of the bromine atom (yellow 
sphere) in a 5-bromouracil residue at position -4 in the template strand (Table 3). The view is from the front 
(Cramer et al, 2001). 
(E) Overview of the -amanitin-inhibited Pol II EC structure. The view is from the side (as in Figure 4, left) 
(Kettenberger et al, 2004). -amanitin (stick model), nucleic acids (pre-templating base as stick model), metal A, 
the bridge helix, and the trigger loop (leucine 1081 as stick model) are highlighted using the color key in (A). Part 
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of the protein is omitted for clarity. 
(F) Sigmaa-weighted 2Fo-Fc electron density map for the nucleic acids in the -amanitin-inhibited EC. The map is 
calculated with phases from the refined model and contoured at 1.0 . Nucleic acids, bridge helix and metal A of 
the refined model are superimposed. The view is as in (E). 
(G) Unbiased initial Fo-Fc electron density map for -amanitin and the folded trigger loop. The map is calculated 
with phases from Pol II alone (Rpb1 residues 1076-1081 and 1092-1096 omitted) and contoured at 2.5 . The 
refined model is superimposed, and helix 37 is omitted for clarity. 
Table 3: X-ray diffraction data and refinement statistics 
Crystal Complete Pol II EC with preserved 
translocation equilibrium 
Complete Pol II EC with -amanitin 
Data collectiona, c   
Space group C2221 C2221 
Unit cell axes (Å) 221.9, 393.1, 283.3 220.6, 394.2, 284.0 
Wavelength (Å) 0.91908 0.91908 
Resolution (Å) 50-3.60 (3.73-3.60)b 50-3.40 (3.52-3.40)b 
Completeness (%) 99.9 (99.9) 99.9 (99.9) 
Unique reflections 277,168 (28,042) 328,642 (32,526) 
Redundancy 3.8 (3.6) 3.6 (3.5) 
Rsym (%) 6.7 (36.8) 13.3 (46.7) 
I/ I 15.9 (3.9) 8.5 (3.0) 
Refinementc   
Amino acid residues  3923 
Nucleic acid residues  48 
Nonhydrogen atoms  32084 
RMSD bonds (Å)  0.009 
RMSD angles (°)  1.5 
Rcryst (%)  25.5 
Rfree (%)  28.8 
Br peaks in anomalous Fourier ( )d 7.9 (at -3) , 4.9 (at -4) 7.8 (at -4) 
aDiffraction data were collected at beamline X06SA at the Swiss Light Source, Villigen, Switzerland. 
bNumbers in parenthesis refer to the highest resolution shell. 
cFriedel pairs treated as different reflections 
dCalculated using phases from Pol II alone after rigid body refinement at 3.6 Å. The observed position in the template DNA is 
given in parenthesis. 
2.2.2 Structure of the -amanitin-inhibited complete Pol II EC 
To investigate the influence of -amanitin on the apparent translocation equilibrium, we 
soaked the inhibitor into an EC crystal, and solved the structure by molecular replacement 
with the Pol II structure (Figure 6E, chapter 2.4.3). We achieved a resolution of 3.4 Å, which 
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revealed even subtle conformational changes. Only a single strong bromine peak was ob-
served that unambiguously revealed the hybrid in the post-translocation register (Figure 6D). 
Strong unbiased difference electron density was observed for the hybrid, for the entire down-
stream DNA, for -amanitin, and for the N-terminal region of the previously disordered trigger 
loop (Figure 6F-G). The structure was rebuilt and fully refined (Table 3, chapter 2.4.3). 
The structure revealed that -amanitin occupies the site observed in the free Pol II core- -
amanitin complex (Bushnell et al, 2002), but shows an altered set of contacts with Pol II 
(Table 4, Figure 7). In particular, the inhibitor formed two previously unobserved hydrogen 
bonds with the Rpb1 residue H1085 within the N-terminal part of the trigger loop (Figure 7). 
Since the trigger loop is disordered in the free EC, -amanitin restricts trigger loop move-
ment. In addition to the previously observed contact of -amanitin to the bridge helix residue 
E822 (Bushnell et al, 2002), several indirect contacts to the bridge helix were observed. In 
particular, -amanitin contacts residues Q767, Q768, S769 and G772 in the Rpb1 loop 23-
24, which in turn binds the bridge helix residues H816 and E822 with its residues Q768 and 
E771, respectively (Table 4, Figure 7). The OH group of the amanitin hydroxyproline residue 
is also near the Rpb1 residue N1082 of the trigger loop, which in turn binds D826 in the 
bridge helix. Thus, an intricate network of hydrogen bonds and other contacts exists between 
-amanitin, the trigger loop, the bridge helix, and loop 23- 24. 
Table 4: Hydrogen bonds between -amanitin and Pol II residues 
-amanitin 
residue 
 
-amanitin atom 
(D, donor; 
A, acceptor) 
Pol II residue 
(BH, bridge helix; 
TL, trigger loop) 
Pol II atom 
(D, donor; 
A, acceptor) 
Length(Å) Present in core Pol II 
-amanitin complex 
(Bushnell et al, 2002) 
2 OD (A) H1085 (TL) NE2 (D) 2.9 no 
2 OD (D) E822 (BH) OE1 (A) 3.1 yes 
2 O (A) S769 N (D) 3.1 yes 
3 OD (A) Q763 NE2 (D) 2.5 no 
3 OG (A) Q760 NE (D) 3.0 no 
3 O (A) Q768 NE2 (D) 3.4 yes 
4 O (A) R726 NH1 (D) 3.2 yes 
4 O (A) Q767 N (D) 2.8 yes 
6 O (A) N723 ND2 (D) 3.2 no 
7 N (D) H1085 (TL) ND1 (A) 3.0 no 
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Figure 7: Contacts between -amanitin and Pol II 
(A) Schematic representation of Pol II- -amanitin contacts. The chemical formula of -amanitin is shown in 
orange. Pol II residues in contact with the inhibitor are depicted in grey. All residues are from Rpb1 except for 
Q763, which belongs to Rpb2 and is in italics. Hydrogen bonds are depicted as green dashed lines, hydrophobic 
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contacts as black dotted lines. Numbers of -amanitin residues are shown next to their C  atoms (Wieland & 
Faulstich, 1991). 
(B-C) Stereo views of -amanitin in its binding pocket. -amanitin is depicted as a stick model with carbon atoms 
in orange. Pol II is shown as a ribbon model in grey with selected residues of the binding pocket as stick model 
with carbon atoms in grey. Nitrogen, oxygen, and sulfur atoms are in blue, red and yellow, respectively. Hydrogen 
bonds are depicted as green dashed lines. Numbers of -amanitin residues are shown next to their C  atoms. 
Pol II elements and residues that contribute to the binding pocket are labeled. Two views are depicted that are 
related by an approx. 180° rotation around a vertical axis. In (B), the view is from the front, similar to Figure 6G, 
and in (C) the view is from the back. 
2.2.3 The trigger loop forms a wedge next to the central bridge helix 
The refined structure showed that binding of -amanitin locked the Pol II EC into a defined, 
and previously unobserved conformational state. The bridge helix remained helical along its 
entire length, but its central part (two turns, residues D826-E833, termed here the central 
bridge helix) was shifted upstream in the direction of the hybrid, as observed in the unbiased 
difference Fourier map (Figure 8A, E-F). The side chain of Rpb1 residue A832 moved by 2.5 
Å in the direction of DNA template translocation. The trigger loop apparently stabilizes the 
shifted conformation of the central bridge helix, as its residue L1081 forms a wedge between 
residue V829 in the bridge helix and residue P1099 in helix 37 (helix G’ in bacterial RNA 
polymerase) (Figure 8B-D). These observations are consistent with a concerted movement 
of the central bridge helix and the trigger loop during translocation. The shift of the central 
bridge helix differs from a previously observed conformational change (Wang et al, 2006) 
that does not include residues T831 and A832, which exhibit the largest movements in this 
work. 
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Figure 8: The -amanitin-inhibited EC structure is a translocation intermediate 
(A) The shifted central bridge helix. The Fo-Fc electron density omit map contoured at 2.5  is shown in blue. The 
map was calculated with phases from the final model lacking the bridge helix (Rpb1 residues 810-845). The 
unbiased Fo-Fc difference map, calculated with initial phases from the Pol II model, is contoured at 2.5  and 
shown in red. The final model of the bridge helix is superimposed, and residues A832 and T831 are highlighted in 
yellow and brown, respectively. 
(B-C) The trigger loop forms a wedge between the bridge helix and helix 37. Top views (as in Figure 4, right) of 
a ribbon model (B) and a space-filling model (C) are shown. The wedging trigger loop residue L1081 and the 
residues flanking it (V829, P1099) are shown in lighter colors. 
(D) The +1 DNA template base adopts a pre-templating position. The initial unbiased Fo-Fc difference map for the 
nucleic acids is shown around the +1 position, contoured at 2.5 . The +1 base in the pre-templating site is 
highlighted in violet. The view is from the top. 
(E-G) Transition from the translocation intermediate to the post-translocation state. The structures of the translo-
cation intermediate and the post-translocation EC (Kettenberger et al, 2004) were superimposed. Metal A, nucleic 
2 Molecular basis of RNA polymerase II translocation and -amanitin inhibition 21
acids, the bridge helix, and the trigger loop including its flanking helices 36 and 37 are shown. The elements of 
the post-translocated EC structure are depicted in lighter colors. Phosphates and bases are depicted as balls and 
sticks respectively. Conformational transitions during translocation step 2 that are required to convert the interme-
diate to the post-translocation EC are indicated with arrows and numbered 1-5. The view is from the side (E) as in 
Figure 6E or from the top (F)-(G), as in Figure 8B. 
2.2.4 The new state of the EC is a translocation intermediate 
The shifted central bridge helix and wedged trigger loop apparently stabilize the nucleic acids 
in a previously unobserved conformation intermediary between the pre- and post-
translocation conformations. Whereas the hybrid adopts the post-translocation position 
(Figure 6D, Figure 8E, Figure 8G), the downstream DNA template adopts an intermediary 
position that corresponds to incomplete translocation (Figure 8E-G). The incoming DNA 
template base at register +1 adopts a previously unobserved position above the central 
bridge helix (Figure 8D-G). We refer to this new template base position as the “pre-
templating” position. In the free EC, the +1 base occupies a standard “templating” position 
opposite the NTP-binding site. In the templating site, the +1 base is twisted by 90° with re-
spect to the +2 base, and stacks against residues A832 and T831 in the central bridge helix 
(Figure 9C-D). In the new structure, the templating site is occluded by the shifted central 
bridge helix, in particular by the A831 side chain (Figure 9C-D). As a consequence, the +1 
base is not twisted with respect to the +2 base, and retains contacts with the +2 base down-
stream, although the base-stacking is discontinued (Figure 8F). 
This analysis identifies the state of the Pol II EC that is induced by -amanitin binding to 
inter-converting pre- and post-translocation ECs as a translocation intermediate. The EC is 
apparently trapped after translocation of the hybrid to the post-translocation position, but 
before complete delivery of the +1 base to the templating position opposite the active site, 
and thus before full establishment of the post-translocation state. 
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Figure 9: Comparisons with bacterial RNA polymerase and possible EC states 
(A-B) Superposition of the trigger loops and bridge helices in the Pol II EC translocation intermediate and the free 
Tth RNA polymerase (Vassylyev et al, 2002). The trigger loop residue L1081 (Pol II) or its homologous residue 
M1238 (Tth) forms a wedge between the bridge helix and helix 37 in Pol II or G' in Tth. The views are from the 
top (A) or the side (B), as in Figure 8B or Figure 6E, respectively. In the Pol II EC translocation intermediate, the 
central bridge helix is shifted, whereas it adopts a flipped-out conformation in the bacterial holoenzyme. 
(C-D) Four possible states of the EC. From top to bottom, the pre-translocation state (Gnatt et al, 2001) (PDB 
1I6H), a potential additional intermediate or a transition state with a modeled flipped-out bridge helix (Vassylyev et 
al, 2002) (PDB 1IW7), the EC translocation intermediate with the shifted bridge helix (this study), and the post-
translocation state (Kettenberger et al, 2004) (PDB 1Y1W) are shown with space-filling models (C) or ribbon 
diagrams (D). The bridge helix residues A832/A1089 (Pol II/Tth) and T831/T1088 (Pol II/Tth) are highlighted in 
yellow and brown, respectively. 
(E-F) Comparison of trigger loop conformations. Pol II EC structures in the post-translocation state (Kettenberger 
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et al, 2004) (PDB 1Y1W), with bound NTP substrate (Wang et al, 2006) (PDB 2E2H), and in the intermediary 
state are superimposed. Nucleic acids and metal A are from the translocation intermediate. The trigger loops of 
the three structures are depicted in dark red (wedged, translocation intermediate), light blue (open, 1Y1W) and 
yellow (closed, 2E2H). (F) Also depicted are the bridge helix (green, translocation intermediate) and the NTP in 
the insertion site (orange, 2E2H). 
2.3 Discussion  
2.3.1 Structure of a translocation intermediate 
Here we report the structure of the Pol II EC in a new, -amanitin-inhibited state, which is 
intermediary between the pre- and post-translocation states. In this intermediate structure, 
the DNA-RNA hybrid adopts the post-translocation position, and the downstream DNA tem-
plate a new position between the pre- and post-translocation register. The +1 base in the 
template strand occupies a previously unobserved pre-templating site above the bridge helix. 
The central bridge helix is shifted upstream and partially occludes the templating site that is 
occupied by the +1 base in the pre- and post-translocation states. The trigger loop adopts a 
position where it forms a wedge that apparently stabilizes the shifted bridge helix. 
2.3.2 Extended NAC model 
Combining the new intermediate structure with known EC structures of Pol II (Gnatt et al, 
2001; Kettenberger et al, 2004; Wang et al, 2006) and a bacterial RNA polymerase 
(Vassylyev et al, 2007b) leads to a model of the NAC (Figure 10) that extends previous 
models (Bar-Nahum et al, 2005; Cramer, 2007; Epshtein et al, 2002; Gnatt et al, 2001; 
Landick, 2004; Vassylyev et al, 2007b). In this model, NTP binds to the post-translocated EC 
in a pre-insertion state that maintains an open, flexible trigger loop (Kettenberger et al, 2004; 
Vassylyev et al, 2007b). Subsequent movement of the NTP to the insertion site goes along 
with closure of the trigger loop and formation of the catalytically active polymerase conforma-
tion (Vassylyev et al, 2007b; Wang et al, 2006). Catalytic incorporation of the nucleotide into 
the RNA leads to pyrophosphate formation. Catalysis per se does most likely not lead to a 
major conformational change in the active center, since the contacts that the trigger loop 
forms with the NTP before catalysis may be maintained with the newly incorporated nucleo-
tide and the pyrophosphate after catalysis. Release of pyrophosphate however would enable 
movement of the trigger loop to the wedged position, facilitating a shift in the central bridge 
helix, which accompanies movement of the nucleic acids to the intermediary state (transloca-
tion step 1). Release of the wedge and relaxation of the bridge helix to the straight position 
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enables movement of the nucleic acids to the post-translocation state (translocation step 2). 
This frees the NTP-binding site for the next incoming substrate and completes the NAC. 
 
Figure 10: Model of the nucleotide addition cycle (NAC) 
Schematic representation of the NAC. The vertical dashed line indicates register +1. For details refer to text. 
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2.3.3 Stepwise translocation and helicase activity of Pol II 
Our data suggest a two-step mechanism of nucleic acid translocation via an intermediate 
(compare Figure 8E-G, Figure 10). During step 1, the hybrid moves from the pre- to the post-
translocation position, and the downstream DNA translocates until the next DNA template 
base (register +2) reaches the pre-templating site. During step 2, the DNA base twists by 
90°, to reach its templating position in the active center (register +1). This twisting is accom-
panied by a flipping of the phosphate backbone group between the DNA template bases +1 
and +2, and a sliding of the downstream DNA to the post-translocation position. In the inter-
mediate, many contacts between the polymerase and the nucleic acids are maintained. This 
likely preserves EC stability during translocation and decreases the energy barrier between 
pre- and post-translocation states, to facilitate movement of the nucleic acids over the Pol II 
surface (Figure 11). 
 
Figure 11: Hypothetical free energy diagram of translocation 
The precise energy level of the pre-translocation state (Pre) and the post-translocation state (Post) and the 
possible intermediates depends on the nucleic acid sequence and probably other factors. The activation energy of 
a hypothetical non-polymerase facilitated translocation (Ea,nopol) is high, because breaking all Pol II-nucleic acid 
contacts is required to reach the corresponding hypothetical transition state (TSnopol). The polymerase presumably 
lowers the activation energy by maintaining many contacts during translocation (Ea,pol). The facilitated-
translocation pathway includes the translocation intermediate (I), shown in this work to be stabilized by -amanitin 
(I -amanitin) (Figure 9C-D). The translocation intermediate may be reached directly via the transition state TS* or via 
another intermediate (I*, grey graph), which may resemble the state found in free bacterial RNA polymerase 
holoenzyme (Vassylyev et al, 2002) (1IW7, Figure 9C-D). 
The EC acts like a helicase on the incoming DNA duplex that apparently melts the base pair 
+2 downstream of the active site (Kashkina et al, 2007; Vassylyev et al, 2007a). Modeling 
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shows that the DNA base in the pre-templating site of the intermediate cannot remain base 
paired with its counterpart in the non-template strand, because the path of the template 
strand strongly deviates from the course of canonical B-DNA as suggested (Kettenberger et 
al, 2004), and the path of the non-template strand is blocked by fork loop 2 (Gnatt et al, 
2001; Kettenberger et al, 2004; Naji et al, 2007; Wang et al, 2006). Available data thus sug-
gest that RNA polymerase melts the downstream DNA base pair during translocation step 1. 
2.3.4 Comparison with bacterial RNA polymerase 
Previous structural and biochemical data for bacterial RNA polymerases had suggested the 
existence of a translocation intermediate and support our findings and interpretations. In the 
structures of the free T. thermophilus (Tth) RNA polymerase holoenzyme (Vassylyev et al, 
2002) and the T. aquaticus (Taq) RNA polymerase bound to two different antibiotics 
(Campbell et al, 2005), the trigger loop residue M1238 intrudes between the bridge helix and 
helix G’ ( 37 in Pol II), similar to the corresponding Pol II trigger loop residue L1081 that 
forms a wedge in the intermediate (Figure 8B-C, Figure 9A-B). In these bacterial polymerase 
structures, the central bridge helix adopts a flipped-out conformation in the region that is 
shifted in the Pol II EC intermediate (Tth/Taq residues 1087-1092). 
RNA-protein crosslinking suggested that the flipped-out conformation reflects an intermediary 
state between the pre- and post-translocation states, and that the bridge helix and trigger 
loop undergo a cooperative structural transition during nucleotide incorporation and translo-
cation (Epshtein et al, 2002). Furthermore, crosslinking studies with E.coli RNA polymerases 
that carried mutations in the C-terminal part of the trigger loop suggested a role of the trigger 
loop in controlling bridge helix movement (Bar-Nahum et al, 2005). Finally, mutation of resi-
due M932 in E.coli RNA polymerase, which corresponds to the wedged trigger loop residue 
L1081 in Pol II, strongly increases the duration of transcriptional pausing (Toulokhonov et al, 
2007), consistent with an important role of this residue in translocation. 
2.3.5 A general translocation mechanism 
These published data and our results converge on a conserved translocation mechanism for 
all multisubunit RNA polymerases, which involves a trigger loop-stabilized EC intermediate 
with an altered structure of the central bridge helix. Due to the very high conservation of the 
active center in all multisubunit RNA polymerases, the observed Pol II EC intermediate con-
formation likely exists in the bacterial EC, although this remains to be shown, since the cen-
tral bridge helix is straight in the first bacterial EC structure (Vassylyev et al, 2007a). It also 
remains to be demonstrated by structural analysis if the flipped-out conformation of the 
bridge helix can be adopted within an EC. Modeling shows that the flipped-out bridge helix 
can be accommodated within the Pol II EC intermediate structure (Figure 9C-D). In this 
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model, the Tth bridge helix residues T1088 and A1089 (T831 and A832 in Pol II) stack 
against the –1 base of the DNA template strand (Figure 9C-D). This EC conformation, if it 
exists, could represent a second, slightly different translocation intermediate (if it can be 
isolated; Figure 11, I*), or the transition state of translocation step 1 (if the central bridge helix 
is only transiently flipped out; Figure 11, TS*). 
2.3.6 The Brownian ratchet and transcription fidelity 
Whereas our studies provide insights into the structural transitions of the EC during translo-
cation, a Brownian ratchet model may explain the directionality of translocation ((Bar-Nahum 
et al, 2005; Landick, 2004; Sousa, 2005) and references therein). The model assumes that 
the ground state of the EC is characterized by an equilibrium between rapidly inter-
converting pre- and post-translocation states (the ratchet), enabled by an oscillation between 
different bridge helix conformations. NTP binding temporarily stops the oscillation, acting like 
a pawl of a ratchet. After nucleotide incorporation, oscillation resumes around the next tem-
plate position. In this model, the energy for translocation comes from Brownian fluctuations, 
and the directionality of translocation results from trapping the forward fluctuation by NTP 
binding and nucleotide incorporation (Figure 10).  
Our data support the Brownian ratchet mechanism. First, the proposed equilibrium between 
pre- and post-translocation states is observed within crystals as coexisting, inter-converting 
states of the EC. Second, the interruption of bridge helix oscillation by NTP binding may be 
rationalized by the mutually exclusive functions of the trigger loop during bridge helix shifting 
and NTP incorporation. The trigger loop residue L1081 (M1238 in Tth/Taq) forms a wedge at 
the shifted bridge helix in the intermediate (Figure 8B-C, Figure 9A-B), but moves by up to 13 
Å to close over the nucleotide during incorporation (Figure 9E-F)(Vassylyev et al, 2007b; 
Wang et al, 2006). Thus swinging of the trigger loop between closed and wedged positions is 
apparently important for the NAC and the Brownian ratchet. 
Trigger loop swinging may also be important for transcription fidelity. We have previously 
shown that an abasic site at template position +1 causes non-templated nucleotide incorpo-
ration (Damsma et al, 2007). This could also occur in the intermediate, which lacks a base in 
the templating position, but exhibits enough space to bind the NTP. However, nucleotide 
incorporation is not favored in the intermediate, since the trigger loop adopts the wedged 
position and is not available for active site closure. 
2.3.7 Single-subunit RNA polymerase and a possible power stroke 
The mechanism of substrate incorporation and translocation was very well studied for the 
single-subunit RNA polymerase from bacteriophage T7 (Temiakov et al, 2004; Yin & Steitz, 
2004). This polymerase shares no sequence similarity with the multisubunit enzymes, but the 
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arrangement of nucleic acids and many mechanistic aspects are similar (Cramer, 2002a; 
Landick, 2004). Structures for the T7 EC include a product complex, which contained the 
nucleic acids in the pre-translocation state after nucleotide incorporation, and retained the 
pyrophosphate (Yin & Steitz, 2004). In this structure, the so-called O-helix binds the DNA 
template strand and the pyrophosphate with its C- and N-terminal ends, respectively. Pyro-
phosphate release apparently triggers a 22° rotation of the O-helix that results in transloca-
tion (Yin & Steitz, 2004). This observation suggested that the catalytic event induces a 
conformational change that actively drives translocation in a power stroke mechanism, an 
attractive alternative to the Brownian ratchet. 
In T7 RNA polymerase, a single structural element, the O-helix, is involved in both pyrophos-
phate binding and template translocation, whereas Pol II uses two elements for these func-
tions, the trigger loop and the bridge helix. A product complex structure is not available for 
Pol II, but the pyrophosphate may retain the trigger loop in a closed position, and only its 
release may re-mobilize the trigger loop, which could then adopt the wedged position, and 
re-establish the translocation equilibrium of a ratchet. Since the trigger loop passes through a 
mobile state between the closed and wedged positions, it cannot directly transmit a possible 
force generated by the catalytic event, just like a rope cannot transmit a pushing force. How-
ever, in molecular motors a power-stroke may be created by a disorder-order transition 
(Block, 2007; Vale & Milligan, 2000). A brownian ratchet mechanism is also supported by 
single-molecule experiments. Galburt et al could explain their observed translocation and 
pausing behavior with a diffusive model, indicative of a brownian ratchet (Galburt et al, 
2007), and Abbondanzieri et al investigated the force dependence of transcription by bacte-
rial RNAP and found that their data could be well described by brownian ratchet, but not 
power stroke models (Abbondanzieri et al, 2005). Taken together, it seems unlikely that in 
Pol II the bridge helix drives forward translocation in an active, power-stroke mechanism. We 
rather remain that the bridge helix accompanies nucleic acid translocation by a passive 
conformational change that is facilitated by the trigger loop wedge.  
2.3.8 Mechanism of -amanitin inhibition 
Our data suggest that -amanitin inhibits Pol II by trapping the wedged trigger loop and 
shifted bridge helix, thereby stabilizing the translocation intermediate (Figure 11). This model 
predicts that -amanitin interferes with both nucleotide incorporation and translocation, and is 
consistent with published functional data. -amanitin strongly reduces the polymerase elon-
gation rate, but does not influence its NTP affinity, and does not abolish multiple nucleotide 
additions (Chafin et al, 1995; Rudd & Luse, 1996). Our elongation assays provided consis-
tent results (Figure 6B). Kinetic studies distinguished three EC conformations with different 
sensitivities for -amanitin (Gong et al, 2004). It appears that these EC conformations, which 
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showed high, medium, or no sensitivity to -amanitin inhibition (Gong et al, 2004), corre-
spond to the intermediate, the pre-, and the post-translocation state, respectively. 
A network of direct and indirect contacts between -amanitin, the bridge helix, and the trigger 
loop apparently underlies polymerase inhibition. Analysis of amanitin derivatives showed that 
the hydroxyl group of the hydroxyproline residue 2 of -amanitin is crucial for inhibition 
(Wieland & Faulstich, 1991; Zanotti et al, 1992). The importance of this hydroxyl group can 
now be ascribed not only to its contact to the bridge helix residue E822 (Bushnell et al, 
2002), but also to its interaction with the trigger loop residue H1085 and a possible contact to 
N1082, which in turn contacts the bridge helix residue E826 (Figure 7). Since -amanitin 
stays attached to the active EC (Rudd & Luse, 1996), some of its contacts with Pol II, in 
particular with the trigger loop and bridge helix, get apparently broken during the NAC. The 
energy required to break these contacts may be responsible for the strong reduction in the 
elongation rate in the presence of the toxin. 
2.4 Specific experimental procedures 
2.4.1 Preparation of Pol II elongation complexes 
Endogenous S. cerevisiae ten-subunit Pol II core enzyme and recombinant Rpb4/7 het-
erodimer were purified as described in chapters 4.2 and 4.4. Nucleic acid scaffolds (Figure 
6A) were annealed by mixing equimolar amounts of synthetic template DNA, nontemplate 
DNA, and RNA in TE buffer (chapter 4.6) at a final concentration of 100 M, heating the 
mixture to 95°C for 5 min, and slow-cooling to 4°C in a thermocycler. Stoichiometric Pol II 
ECs were assembled by incubating core Pol II for 10 min with 2 molar equivalents of nucleic 
acid scaffold, followed by 20 min incubation with 5 molar equivalents of recombinant Rpb4/7 
in assembly buffer (chapter 4.6) at 20°C. The complexes were purified by size exclusion 
chromatography (Superose 6 10/300 GL) in Pol II buffer.  
2.4.2 Crystallization and crystal treatment 
Purified Pol II ECs were concentrated to 3.5-4.5 mg/ml and an additional amount of the 
nucleic acid scaffold was added prior to crystallization to a final concentration of 2 M. Crys-
tals were grown at 22 °C with the hanging drop vapor diffusion method by mixing 2 l of 
sample solution with 1 l of reservoir solution (NH4-Na-acetate crystallization solution, chap-
ter 4.7). Crystals were harvested in mother solution after 10-20 days, when they had reached 
their maximum size (approx. 0.4 x 0.3 x 0.2 mm). Crystals were transferred stepwise over 5 
hours to mother solution containing additionally 0-22 % glycerol. For complex formation with 
-amanitin (Sigma), the crystals were incubated for 4 hours in mother solution containing 
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additionally 22 % glycerol, 5 mM magnesium acetate and 100 μM -amanitin. Crystals were 
slowly cooled to 8 °C, and flash-cooled by plunging into liquid nitrogen.  
2.4.3 X-ray structure analysis 
Diffraction data were collected in 0.25 ° increments at the protein crystallography beamline 
X06SA of the Swiss Light Source using the new Pilatus 6M pixel detector (Broennimann et 
al, 2006) (Table 3). Raw data were processed with XDS (Kabsch, 1993). Structures were 
solved by molecular replacement with the program Phaser (McCoy et al, 2005), using the 
structure of the complete 12-subunit Pol II elongation complex without nucleic acids as a 
search model (PDB 1Y1W, (Kettenberger et al, 2004)). The molecular replacement solution 
was subjected to rigid body refinement with CNS version 1.2 (Brunger, 2007) using five rigid 
groups (core, jaw-lobe, shelf, clamp, Rpb4/7). Model building was carried out with programs 
Coot (Emsley & Cowtan, 2004), O (Jones et al, 1991) and Moloc (Gerber & Muller, 1995). 
The nucleic acids were built into the initial Fo-Fc electron density map. The register of the 
nucleic acids was unambiguously defined by bromine labeling as described (Brueckner et al, 
2007). Shifted parts of the trigger loop and the bridge helix were manually rebuilt into omit 
maps (Figure 6G, Figure 8A). A model for -amanitin (Bushnell et al, 2002) was manually 
placed into the initial Fo-Fc map (Figure 6G) and further adjusted manually and by restrained 
real space refinement with Moloc. Atomic positions and B-factors were refined with CNS 
version 1.2. Refinement parameters for -amanitin were generated using Moloc. Refinement 
was monitored with the free R factor, calculated from the same 2 % set of excluded reflec-
tions as in refinement of complete Pol II (Armache et al, 2005) and the complete Pol II EC 
(Kettenberger et al, 2004), extended to the higher resolution of 3.4 Å. The increase in resolu-
tion was apparently due to differences in the crystallization protocol, use of a new, highly 
sensitive pixel detector with increased signal/noise ratio, and an improved processing strat-
egy, including the use of XSCALE with zero dose extrapolation for scaling and CNS version 
1.2 with bulk solvent parameter grid search for refinement and map calculation. Structural 
superpositions were performed with the secondary structure matching function of Coot (Ems-
ley and Cowtan, 2004). Figures were prepared with Pymol (DeLano, 2002). 
2.4.4 Transcript extension assays 
Stoichiometric ECs of complete Pol II, containing the 10-subunit core and Rpb4/7, were 
assembled and purified as described above, but in transcription buffer without MgSO4 (20 
mM Hepes pH 7.6, 60 mM ammonium sulfate, 10 M ZnCl2, 10 % glycerol, and 10 mM DTT, 
compare chapter 4.6). -amanitin-inhibited Pol II ECs were prepared by incubating ECs at 20 
°C with -amanitin for 10 min. The RNAs used for extension assays were identical to those 
used for structural studies, except for five additional nucleotides (5’-UGCAU-3’) and a fluo-
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resceine label at their 5’-end. For transcript extension, ECs or -amanitin-inhibited ECs were 
incubated with NTPs and 10 mM magnesium sulfate at 28 °C in transcription buffer. Reac-
tions were stopped by incubating with an equal volume of gel loading buffer (90% (v/v) for-
mamide, 50 mM EDTA pH 7.4) for 5 min at 95 °C. The RNA products were separated by 
denaturing gel electrophoresis (0.5 pmol RNA per lane, 0.4 mm 20 % polyacrylamide gels 
containing 7 M urea, 50-55 °C) and visualized with a Typhoon 9400 scanner (GE 
Healthcare). 
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3 CPD damage recognition by transcribing RNA polym-
erase II 
3.1 Introduction 
Ultraviolet light damages cellular DNA by inducing dimerization of adjacent pyrimidines in a 
DNA strand. The resulting cyclobutane pyrimidine dimer (CPD) lesions can block transcrip-
tion and replication, and are a major cause of skin cancer (Mitchell et al, 2003). Cells elimi-
nate CPDs by nucleotide excision repair (NER). A very efficient NER subpathway is 
transcription-coupled DNA repair (TCR), which specifically removes lesions from the DNA 
strand transcribed by Pol II (Saxowsky & Doetsch, 2006). Pol II stalls when a CPD in the 
DNA template strand reaches the enzyme active site (Mei Kwei et al, 2004; Tornaletti et al, 
1997). Pol II stalling apparently triggers TCR by recruitment of a transcription-repair coupling 
factor (Rad26 in yeast, CSB in humans) and factors required for subsequent steps of NER, 
including TFIIH, which comprises helicases that unwind DNA (Saxowsky & Doetsch, 2006; 
Svejstrup, 2002). Endonucleases then incise the DNA strand on either side of the lesion, 
resulting in a 24-34 nucleotide fragment (Mu & Sancar, 1997; Selby et al, 1997; Tremeau-
Bravard et al, 2004). The obtained DNA gap is subsequently filled by DNA synthesis and 
ligation (Prakash & Prakash, 2000; Sancar, 1996). 
3.2 Results and discussion 
3.2.1 The molecular mechanism of CPD damage recognition by RNA 
polymerase II 
To elucidate CPD recognition by transcribing Pol II, we carried out a structure-function analy-
sis of elongation complexes containing in the template strand a thymine-thymine CPD. Elon-
gation complexes were reconstituted from the 12-subunit Saccharomyces cerevisiae Pol II 
and nucleic acid scaffolds as previously described (Kettenberger et al, 2004), except that the 
mobile upstream DNA and the non-template strand in the transcription bubble were omitted 
(minimal nucleic acid scaffold, chapter 3.2.5.1). A chemical analogue of a CPD lesion was 
incorporated at register +2/+3 of the template strand, directly downstream of position +1, 
which denotes the substrate addition site (scaffold A, Figure 12A; chapter 3.2.5.2). The crys-
tal structure of the resulting elongation complex A was determined (Figure 12B; chapter 
3.3.3), and the register of the nucleic acids was unambiguously defined by bromine labeling 
(Table 5; Figure 13C). The overall structure of complex A was nearly identical to the com-
plete Pol II elongation complex (Kettenberger et al, 2004) and very similar to elongation 
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complex structures of the Pol II core enzyme (Gnatt et al, 2001; Westover et al, 2004a) 
(chapter 3.2.5.3). The template strand enters the active site, and continues into an eight base 
pair hybrid duplex with RNA, which occupies the upstream positions –1 to –8 (Figure 12B; 
chapter 3.2.5.1). In contrast to the damage-free elongation complex (Kettenberger et al, 
2004), downstream DNA entering the cleft is mobile, indicating that the CPD at positions 
+2/+3 loosens the grip on downstream DNA (chapter 3.2.5.2). 
Table 5: X-ray diffraction data and refinement statistics of CPD lesion containing Pol II ECs A-D. 
CPD-containing elongation 
complex  
A B C D 
Data collectiona 
Space group C2221 C2221 C2 C2221 
Unit cell axes (Å) 222.2, 392.2, 284.0 223.6, 393.5, 283.5 394.4, 221.9, 283.1 222.6, 392.8, 282.9 
Unit cell  angle (°) 90 90 90.6 90 
Wavelength (Å) 0.9191 0.9190 0.9192 0.9189 
Resolution range (Å) 50-3.8 (3.94-3.80)b 50-4.0 (4.14-4.00)b 50-3.8 (3.94-3.80)b 50-3.80 (3.94-3.80)b 
Unique reflections 120,477 (11,664) 104,987 (10,232) 238,284 (23,709) 121,341 (11,999) 
Completeness (%) 99.0 (96.8) 99.8 (98.2) 99.6 (99.6) 99.9 (99.7) 
Redundancy 4.6 (3.4) 5.8 (4.5) 3.3 (3.2) 5.1 (4.0) 
Mosaicity (°) 0.50 0.50 0.47 0.34 
Rsym (%) 12.0 (45.4) 8.7 (41.1) 9.8 (43.1) 8.3 (37.3) 
I/ (I) 10.3 (2.1) 15.8 (3.1) 10.2 (2.3) 17.1 (3.2) 
Refinement 
Nonhydrogen atoms 31,665 32,016 63,934 32,005 
RMSD bonds 0.010 0.009 0.010 0.009 
RMSD angles 1.55 1.52 1.60 1.55 
Rcryst (%) 27.0 29.2 25.7 26.9 
Rfree (%) 28.0 30.1 27.5 28.8 
Br peak in anomalous 
Fourier ( ) 
11.4 5.3 10.7, 10.6 6.4 
PDB accession code 2ja5 2ja6 2ja7 2ja8 
aAll diffraction data were collected at the Swiss Light Source, Paul-Scherrer-Institut, Villigen, Switzerland. 
bNumbers in parenthesis correspond to the highest resolution shell. 
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Figure 12: Pol II elongation complex structures with thymine-thymine CPD lesions in the template. 
(A) Nucleic acid scaffolds A-D. The color code is used throughout. Filled circles denote nucleotides with interpret-
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able electron density that were included in the structures in (B). Open circles denote nucleotides with non-
interpretable or absent electron density. 
(B) Structure of nucleic acids in the Pol II elongation complexes A-D. The view is from the side as in Figure 4, left. 
Figures prepared with PYMOL (DeLano Scientific). 
(C) Overview of complex C with a CPD lesion at the active site. The view is as in (B). Protein is in grey, the bridge 
helix in green. The CPD is shown as a stick model in orange. A large portion of the second largest Pol II subunit 
was omitted for clarity. 
(D) Superposition of nucleic acids in structures A-D. The protein molecules were superimposed and then omitted. 
The nucleic acids are depicted as ribbon models, the CPDs as stick models. Upper and lower views are related 
by a 90° rotation around a horizontal axis. 
 
Figure 13: Electron density maps of CPD lesion containing Pol II ECs. 
Electron density maps were calculated from the datasets shown in Table 5. The final model of the nucleic acids, 
metal A and the bridge helix are superimposed (color code as in Figure 12A). 
(A) Unbiased Fo-Fc difference Fourier map (green) of complex C calculated after rigid body refinement with 
phases from the complete Pol II elongation complex without nucleic acids, contoured at 2.5 . The view is as in 
Figure 12B (side view). 
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(B) 2Fo-Fc map (grey) of complex C calculated with phases from the refined structure C and contoured around the 
nucleic acids and the bridge helix (side chains shown as sticks) at 1.0 . 
(C) Bromine anomalous difference Fourier maps (pink) calculated with phases from the refined structures A, B, C, 
and D, contoured at 6.0 , 3.8 , 6.0 , and 3.8 , respectively. The observed peak heights are between 5.3  
and 11.4  (Table 5), and coincide with the location of the bromine atom in a 5-bromouracil residue incorporated 
in the DNA template strand, thereby defining the register of nucleic acids. When the anomalous difference Fourier 
maps in complexes B and D were contoured at the low level of 2.5 , there were no peaks at potential bromine 
positions in neighboring nucleotides. Thus there were no significantly populated alternative states with different 
nucleic acid registers, such as non-back-stepped states in complexes B and D. However we cannot exclude that 
a very minor portion of the complexes adopt a non-backstepped state. We can, however, exclude that the lower 
bromine peak heights in complexes B and D result from diffraction data collection at a wavelength different from 
the bromine anomalous peak since crystals were subjected to fluorescence scans and measured at the highly 
wavelength-stable SLS beamline PX1. With respect to (B), the models in (C) are rotated by 90° around a vertical 
axis. 
To investigate Pol II stalling at the CPD lesion, we incubated complex A with nucleoside 
triphosphate (NTP) substrates, followed RNA extension by fluorescence-monitored capillary 
electrophoresis, and identified the RNA products by mass spectrometry (Figure 14; Figure 
15; chapter 3.3.4). After incubation with a physiological concentration of 1 mM NTPs for one 
hour, the RNA was extended by three nucleotides (Figure 14A), but not any further. Thus the 
complex stalled after nucleotide incorporation opposite both CPD thymines. A time course 
showed that the first incorporation event was fast, consistent with a free substrate site in 
complex A (Figure 12A-B; Figure 14B; chapter 3.2.5.4). The second and third incorporation 
events however were progressively slower, with rate constants of approx. 16 h-1 and 2.4 h-1, 
respectively (Figure 14A-B). 
The second incorporation event is opposite the 3'-thymine of the CPD. Efficient incorporation 
required a concentration of 1 mM NTPs. Lower substrate concentrations limited RNA exten-
sion to one nucleotide after 5 min (Figure 17A). In the undamaged elongation complex tem-
plate bases in positions +1 and +2 are twisted against each other by 90° (Kettenberger et al, 
2004). To enter the active site the +1 template base presumably rotates by 90° from the "pre-
templating" to the templating position (chapter 2.3.3). The CPD thymines are covalently 
linked and therefore can only rotate together. Modeling suggests that rotating the 3'-thymine 
to the +1 templating position would result in a severe clash of the 5'-thymine with the bridge 
helix in the straight conformation (not shown). Therefore, a significant conformational change 
in the elongation complex would be required to allow the 3'-thymine of the CPD to serve as a 
templating base for a nucleotide incorporation. 
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Figure 14: RNA extension assays 
(A) Electropherograms of time-dependent extension of RNA in complex A. A stoichiometric complex of complete 
Pol II and scaffold A (Figure 12A) was incubated with 1 mM ATP, CTP, GTP and UTP. Reactions were stopped at 
the given time points. RNA products were subjected to fluorescence-monitored capillary electrophoresis, and 
identified by mass spectrometry. Signals for different RNAs are highlighted in different colors. 
(B) Quantification of time-dependent extension of RNA in complex A. Electropherogram signals in (A) were 
integrated and the relative amount of RNA product plotted against incubation time. 
(C) Specific uridine monophosphate (UMP) misincorporation opposite the CPD 5’-thymine. Stoichiometric com-
plexes of complete Pol II and scaffold C were incubated with 1 mM of each NTP for 40 min. 
(D) Model for UMP misincorporation. In the upper panel, the structure of an undamaged Pol II elongation complex 
with a non-hydrolysable NTP analogue (PDB 1Y77) was superposed on structure C. Depicted are the base pair at 
position +1 in 1Y77 (violet), and the CPD in structure C (orange). As modeled in the lower panel, the CPD 5’-
thymine could form two hydrogen bonds with an incoming UTP. 
(E) Lesion bypass transcription. RNA in complex D (5’-AU-3’ opposite the CPD) was not extended after 20 min 
incubation with 1 mM of NTPs. Bypass was enabled under identical conditions by replacement of the RNA 3’-
terminal UMP with adenosine monophosphate (AMP) (5’-AA-3’ opposite the CPD, scaffold DU A, Figure 16). 
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Figure 15: Mechanism of CPD recognition by transcribing Pol II. 
Schematic representation of RNA extension in complex A. The initial RNA (top) corresponds to the non-extended 
RNA of scaffold A. The translocation barrier and the translocation block are indicated with a dashed and a solid 
horizontal line, respectively. The artificial situation leading to lesion bypass (Figure 14E) is depicted at the bottom. 
To test this, we included a CPD at positions +1/+2 of the scaffold, and solved the crystal 
structure of the resulting complex B (Figure 12A-B). The CPD was observed at register 
+2/+3, indicating that it is not stably accommodated at positions +1/+2. Pol II had apparently 
“back-stepped” by one position, consistent with disfavored forward translocation (Figure 15; 
chapter 3.2.5.5). When complex A was crystallized under conditions with no magnesium 
(NH4-Na-acetate crystallization solution, chapter 4.7), a strong bromine peak was observed 
at position -5, indicating a hyper-translocated state with the CPD located at positions +1/+2 
(Cheung, A., personal communication). Clear unbiased difference electron density for the 
CPD was observed above the bridge helix, overlapping with the +1 pre-templating position 
and the +2 template position in the translocation intermediate (chapter 2), whereas no elec-
tron density was found in the +1 templating position. In conclusion, a complex with the 3'-
thymine of the CPD in the +1 templating position could not be isolated. Such a state probably 
does not exist, or at most only transiently. This can be rationalized by assuming that the 
necessary distortion of the EC is energetically disfavored. Instead, the incorporation of ade-
nine opposite of the 3'-thymine could be a non-templated incorporation event. It was demon-
strated that opposite of an abasic site Pol II prefers the incorporation of adenine over other 
nucleotides (Damsma et al, 2007). For another dinucleotide lesion, the 1,2-d(GpG) in-
trastrand crosslinks (cisplatin-lesion), preferred addition of adenine opposite the 3'-guanine 
was reported (chapter 3.2.4) (Damsma et al, 2007). Taken together, it is plausible that the 
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incorporation of an adenine opposite of the 3'-thymine of a CPD is non-templated. However, 
it remains to be shown directly. 
 
 
 
Figure 16: Additional scaffolds used in RNA extension assays. 
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Figure 17: Additional selected RNA extension assays. 
(A) RNA extension at varying NTP concentration. Stoichiometric complexes of complete Pol II and scaffold A 
were incubated for 5 min with different concentrations of ATP. At 1 mM ATP, the translocation barrier is over-
come, but only two extension steps are possible since adenine is not incorporated opposite the CPD 5’-thymine 
(Figure 14A-C). At 0.01 mM ATP, the translocation barrier is not overcome and the RNA is extended by only one 
nucleotide, whereas an undamaged template with the same sequence (scaffold A CPD, Figure 16) is readily 
extended at this ATP concentration and the same incubation time, providing a positive control (box). 
(B) Kinetics of the final incorporation step. A stoichiometric complex of complete Pol II and scaffold C was incu-
bated with 1 mM of ATP, CTP, GTP and UTP. The relative amount of RNA extension product is plotted against 
the incubation time (compare Figure 14B). This reaction corresponds to the third incorporation event in complex A 
(compare Figure 14A-C). 
(C) Lesion bypass transcription using an alternative nucleic acid scaffold. To exclude construct bias (mismatch at 
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position -8 of scaffold D), lesion bypass was also examined using scaffold C with an additional adenine at the 
RNA 3’-end (5’-AA-3’ opposite the CPD, scaffold C+A, Figure 16). Pol II could efficiently bypass the lesion in this 
scaffold after 20 min incubation with 1 mM of ATP, CTP, GTP and UTP. When scaffold C with an additional UMP 
was used (5’-AU-3’ opposite the CPD, scaffold C+U, Figure 16), no bypass was observed after identical condi-
tions.  
(D) Highly inefficient T-U mismatch extension. To examine bypass of a T-U mismatch, the CPD in the template 
DNA of scaffold D was replaced by two thymines (Scaffold D CPD, Figure 16). After 20 min incubation with 1 mM 
of ATP, CTP, GTP and UTP, a small fraction of elongation complexes had bypassed the mismatch (approx. 5 %). 
Without the mismatch (Scaffold D CPD_U A, Figure 16) efficient RNA extension to the run-off product was observed 
under identical conditions, providing a positive control. 
(E) TFIIS-induced transcript cleavage in dinucleotide increments. Backtracking and transcript cleavage by TFIIS 
was analyzed using scaffold C with an additional UMP at the RNA 3’-end (scaffold C+U, Figure 16). The resulting 
elongation complex corresponds to a complex naturally stalled at a CPD lesion. Incubation time was 10 min, and 
1 or 2 molar equivalents of TFIIS were used. Shortened RNA products are indicated (RNA-2, RNA-4, RNA-6, 
initial RNA shortened by 1, 2, and 3 dinucleotides, respectively). 
After the non-templated adenine addition a subsequent translocation step may allow rotation 
of the whole CPD into the active site, where it would occupy the template positions -1/+1. To 
test this and to investigate the very slow incorporation of the third nucleotide into complex A, 
we included a CPD at positions –1/+1, and solved the structure of the resulting complex C. 
The CPD was seen stably accommodated in the active site, with a Watson-Crick base pair 
between the CPD 3'-thymine and the adenine at the 3' end of the product RNA. The NTP-
binding site opposite the CPD 5’-thymine was free (Figure 12A-C; Figure 18). We therefore 
used complex C to monitor incorporation of different NTPs. Only UTP led to nucleotide incor-
poration opposite the 5’-thymine (Figure 14C), generally consistent with data for human Pol II 
(Mei Kwei et al, 2004). This misincorporation was very slow, with a rate constant of approx. 
2.9 h-1, comparable with the rate determined for the third nucleotide incorporation into com-
plex A (Figure 17B; chapter 3.2.5.4). Since translocation is not required for nucleotide incor-
poration in complex C, the rate-limiting step in reaching the stalled state is the slow uridine 
monophosphate (UMP) misincorporation, not CPD translocation from positions +1/+2 to –
1/+1. Consistent with misincorporation opposite the CPD 5’-thymine, RNA in complex A was 
extended by only two residues, instead of three, when only ATP was present (Figure 17A, 
Figure 14A). 
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Figure 18: Active site of Pol II in complex C 
View as in Figure 12B. Color code as in Figure 12A. Protein side chains within 5 Å of the CPD are shown as grey 
sticks. Italics are used to distinguish Rpb2 from Rpb1 residues. 
Specific UMP misincorporation may be explained with the complex C structure. Whereas the 
CPD 3’-thymine occupies the same position as in the undamaged elongation complex 
(Kettenberger et al, 2004), the CPD 5’-thymine is tilted by approx. 40°, and is shifted down-
wards by more than 2 Å into a wobble position, with the O4 atom at the location normally 
occupied by the N3 atom (Figure 14D). Provided that binding of the incoming NTP 
(Kettenberger et al, 2004; Westover et al, 2004a) is unaffected, the wobbled 5’-thymine could 
form two hydrogen bonds with UTP, whereas only one hydrogen bond would be possible 
with other NTPs (Figure 14D). Attempts to visualize the CPD 5’-thymine-uracil mismatch 
crystallographically were unsuccessful (chapter 3.2.5.7).  
These results suggested that Pol II stalls because translocation of the CPD 5’-thymine-uracil 
mismatch from position +1 to position –1 is strongly disfavored. This translocation event 
would move the damage-containing mismatch into the DNA-RNA hybrid, and the resulting 
distortion of the hybrid would destabilize the elongation complex (Kireeva et al, 2000) (chap-
ter 3.2.5.8). To test this model, we incorporated the CPD at positions –2/-1 of the scaffold, 
including a UMP residue opposite the 5’-thymine, and solved the structure of the resulting 
complex D (Figure 12A-B). In this structure, Pol II had apparently back-stepped by one posi-
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tion, and the CPD was again located to positions –1/+1 in the active site, consistent with 
disfavored translocation (chapter 3.2.5.5). 
Disfavored translocation of the CPD from position –1/+1 to –2/-1 may result from distortions 
due to the CPD and/or due to the mismatch. To distinguish these possibilities, we tested if 
Pol II extends the RNA in a variant of complex D with a matched CPD 5’-thymine-adenine 
base pair (Scaffold DU A, Figure 16). Surprisingly, this RNA was extended to the run-off 
transcript (Figure 14E; chapter 3.2.5.9). Thus Pol II would bypass a CPD lesion if it could 
incorporate adenine opposite the CPD 5’-thymine. To test whether a T-U mismatch base pair 
alone is sufficient to stall Pol II, we used complex D, but without CPD, in RNA extension 
assays (Scaffold D CPD, Figure 16). Only a small portion of the RNA was extended (Figure 
17D). Taken together, Pol II stalling does not result from CPD-induced distortions per se, but 
from CPD-directed misincorporation. In contrast, DNA polymerases can correctly incorporate 
adenine opposite both CPD thymines, and, dependent on the type of polymerase, this can 
lead to stalling or lesion bypass (Li et al, 2004; Ling et al, 2003). 
3.2.2 A topological model for transcription-coupled DNA repair 
In all CPD-containing structures, the polymerase conformation is unchanged. This argues 
against allosteric models of TCR, which assume an incoming lesion causes a conformational 
change in Pol II that triggers recruitment of repair factors. In complexes B and D, down-
stream DNA is repositioned in the polymerase cleft (Figure 12D). However, DNA reposition-
ing cannot support an allosteric mechanism, since it occurs only in back-stepped complexes, 
which would not form when NTPs are present. A damage-stalled complex could alternatively 
be detected via exposure of the lesion by Pol II backtracking (Donahue et al, 1994). The 
transcript cleavage factor TFIIS induces backtracking of a CPD-stalled complex (Figure 17E; 
chapter 3.2.5.10), but TFIIS is not required for TCR in vivo (Verhage et al, 1997). The lesion 
could also be exposed after polymerase bypass or dissociation from DNA. The latter mecha-
nism underlies bacterial TCR, which involves the ATPase Mfd (Deaconescu et al, 2006). 
However, the related eukaryotic ATPase CSB does neither trigger polymerase dissociation 
nor bypass (Selby & Sancar, 1997b). 
An alternative model for eukaryotic TCR that combines and extends previous models (Sarker 
et al, 2005; Svejstrup, 2003; Tremeau-Bravard et al, 2004) can explain recognition of the 
stalled complex without allostery or exposure of the lesion (Figure 19). Complexes that stall 
at an arrest site are rescued by TFIIS (Wind & Reines, 2000). Complexes that stall at a non-
bulky lesion are rescued by CSB-induced lesion bypass (Lee et al, 2002). In both cases, 
transcription resumes. At a CPD lesion, however, CSB counteracts TFIIS-induced backtrack-
ing (Laine & Egly, 2006; Selby & Sancar, 1997a), resulting in a stably stalled complex, and 
opening a time window for assembly of the repair machinery. TFIIH catalyzes extension of 
the transcription bubble. TFIIH contains two subunits with helicase activity, XPB and XPD. 
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XPB is required for transcription and repair and is located at the downstream part of the cleft 
during transcription initiation (Kim et al, 2000; Miller & Hahn, 2006; Tantin, 1998). The ob-
served repositioning of downstream DNA in the CPD-containing structures B and D shows 
that downstream DNA in the elongation complex can occupy different positions, and a 
change in the position of downstream DNA may be required for TFIIH action during TCR. 
There is evidence that the upstream incision site is rendered accessible by TFIIH action 
(Sarker et al, 2005) and this may be due to the second helicase of TFIIH, XPD. Extension of 
the transcription bubble permits dual incision of the template strand on the Pol II surface 
(Selby et al, 1997; Tremeau-Bravard et al, 2004). The lesion-containing DNA fragment and 
the RNA transcript are removed together with Pol II, although this requires more than dual 
incision (Tremeau-Bravard et al, 2004). The remaining gapped DNA is repaired. Pol II may 
be recycled, circumventing its ubiquitination and destruction (Woudstra et al, 2002). In con-
clusion, our data establish the molecular mechanism of CPD recognition by a cellular RNA 
polymerase, and provide a structural framework for further analysis of eukaryotic TCR. 
 
Figure 19: Topological model for transcription-coupled DNA repair. 
The lesion-containing Pol II EC is shown schematically. The view and color code are as in Figure 12A-C. An 
orange star and a magenta sphere indicate the CPD lesion and the active site, respectively. The upstream DNA 
was placed on Pol II on the basis of its location in the bacterial RNA polymerase-promoter complex (Murakami et 
al, 2002). The nontemplate strand in the bubble region was modeled. TFIIH helicase subunits XPD and XPB may 
be involved in extending the transcription bubble in the upstream and downstream direction, respectively, to 
enable dual incision. Modeling shows that incisions could occur at the two edges of an extended bubble around 
10-15 nucleotides upstream (3’) and around 15-20 nucleotides downstream (5’) of the lesion. 
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3.2.3 Comparison of CPD recognition by different polymerases 
The mechanism of CPD recognition by Pol II is likely the same in Pol I and Pol III, since their 
active centers are conserved (Jasiak et al, 2006; Kettenberger et al, 2004). However, DNA 
polymerases recognize and process a CPD differently. The DNA polymerase of bacterio-
phage T7 and the lesion-bypass polymerase Dpo4 incorporate adenosine monophosphate 
(AMP) opposite the CPD 5’-thymine (Li et al, 2004; Ling et al, 2003), in contrast to Pol II, 
which incorporates UMP. In addition, dATP binds differently opposite the CPD 5’-thymine in 
these two DNA polymerases (Li et al, 2004; Ling et al, 2003). Therefore, detailed structure-
function studies of each type of DNA lesion in the context of each polymerase family are 
required to unravel the mechanisms of lesion recognition and processing. 
3.2.4 Comparison with the mechanism of cisplatin damage recognition 
The anticancer drug cisplatin (cis-diamminedichloroplatinum(II)) forms 1,2-d(GpG) DNA 
intrastrand cross-links (cisplatin lesions) that stall Pol II and trigger transcription-coupled 
DNA repair (Corda et al, 1991; Corda et al, 1993; Jung & Lippard, 2006; Kartalou & Essig-
mann, 2001; Tornaletti et al, 2003; Wang & Lippard, 2005). Whereas in the CPD lesion two 
neighboring thymine bases are covalently linked with a cyclobutane ring including the C5 and 
C6 atoms, in a cisplatin lesion the platinum atom coordinates the N7 atoms of two adjacent 
guanines in a DNA strand (Figure 20). The cisplatin lesion can be stably accommodated in a 
Pol II EC at position +2/+3 of the template strand, but translocation to position +1/+2 is disfa-
vored (Figure 21)(Damsma et al, 2007), which is both also the case for the CPD lesion. 
There is strong evidence that adenine is incorporated in a non-templated fashion opposite of 
the cisplatin 3'-guanine, as it is also proposed for the CPD lesion (chapter 3.2.1). However, 
unlike the CPD, the cisplatin lesion cannot be stably accommodated in the active site (posi-
tions -1/+1). There are two possible causes. First, the cisplatin lesion is a more bulky 
dinucleotide lesion than the CPD. The maximum lateral dimension is 7.2 Å (N2-N2 distance) 
compared to 5.3 Å (O2-O2 distance) for the CPD (Figure 20). Modeling suggested, that a 
conformational change of the bridge helix would be required to accommodate the lesion in 
the active site (Figure 22). Second, a G•A mismatch base pair would be formed at position -1 
in contrast to a stabilizing T-A base pair in the case of the CPD. 
In conclusion, the mechanism of recognition by transcribing Pol II is different for both dinuc-
leotide lesions (Figure 23). At a cisplatin lesion, Pol II stalls because the lesion cannot be 
delivered to the active site, whereas it stalls at a CPD lesion after delivery to the active site 
and specific UMP misincorporation opposite the 5'-thymine. Bypass of the CPD lesion is only 
possible by artificially replacing the resulting T•U mismatch by a T-A match. Bypass of the 
cisplatin lesion is possible by artificially providing a starting transcript, extending at least up to 
the 3'-guanine (Figure 23). Remarkably, bypass is possible in presence of a G•A mismatch 
with the 3'-guanine of the cisplatin dimer. 
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Figure 20: Structural comparison of two different DNA dinucleotide lesions 
Stick models of the dinucleotide lesions are shown with carbon atoms in grey, nitrogen in blue, oxygen in red and 
phosphorus in orange. 
(A) The 1,2-d(GpG) intrastrand platinum cross-link (GG cisplatin lesion). The maximum lateral dimension is 7.1 Å 
(N2-N2 distance) 
(B) The thymine-thymine cyclobutane pyrimidine dimer lesion (TT CPD lesion). The maximum lateral dimension is 
5.3 Å (O2-O2 distance). 
 
Figure 21: Structure of a cisplatin-damaged Pol II elongation complex 
(A) Nucleic acid scaffold (scaffold A in (Damsma et al, 2007)). Filled circles denote nucleotides with interpretable 
electron density that were included in the structure in (B); open circles denote nucleotides with uninterpretable or 
absent electron density. 
(B) Structure of nucleic acids in a cisplatin-damaged Pol II elongation complex (complex A in (Damsma et al, 
2007)). Final 2Fo-Fc electron density map for the nucleic acids is shown (blue, contoured at 1.0 ). Anomalous 
difference Fourier map reveals the location of the platinum atom (magenta, contoured at 15 ). 
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Figure 22: Model of the cisplatin lesion in the active site of Pol II 
Modeling of the cisplatin lesion at positions +1/-1. A cisplatin lesion was manually placed such that it superim-
poses with template nucleotides at the active center positions +1 and -1 of complex A. Owing to some close 
contacts, in particular with Thr831 in the bridge helix, slight conformational changes are required to accommodate 
the lesion. 
 
Figure 23: Different mechanisms of Pol II stalling at dinucleotide lesions. 
(A) Pol II stalling at the cisplatin lesion, shown as a schematic representation of RNA extension in complex A. The 
initial RNA (top) corresponds to the non-extended RNA of scaffold A. Dashed line represents translocation barrier. 
The artificial conditions leading to lesion bypass are depicted at the bottom. 
(B) Pol II stalling at a CPD lesion (compare Figure 15, page 38). 
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3.2.5 Additional detailed information 
3.2.5.1 Minimal nucleic acid scaffolds and hybrid length in elongation com-
plexes. 
The structure of the complete Pol II elongation complex showed seven DNA-RNA base pairs 
at positions –1 to –7, with Watson-Crick edges of the bases at position –8 at the upstream 
end of the hybrid about 4 Å apart (Kettenberger et al, 2004). This slightly increased base 
distance may have resulted from a bulky A-A DNA-RNA mismatch at position –9. The CPD 
lesion containing Pol II EC structures A and C contain a smaller A-C mismatch at position -9, 
and show a hybrid length of eight base pairs (positions –1 to –8). To test if the scaffold de-
sign influences the outcome of the biochemical results, we tested complete scaffolds that 
included a nontemplate strand in biochemical assays. The results were essentially not influ-
enced by the nontemplate strand, showing that the use of minimal scaffolds in the functional 
studies is justified. The use of the minimal scaffolds in structural studies is justified by the 
highly similar nucleic acid structure observed in the complete elongation complex structure 
(Kettenberger et al, 2004). 
3.2.5.2 Use of a CPD analogue. 
A thymine-thymine CPD formacetal analogue was used that carries a methylene group in-
stead of a phosphate group between the two thymines (Butenandt et al, 2000) (chapter 
3.3.1). As a consequence there is a missing negative charge in the DNA template strand 
backbone between positions +2 and +3, which may be partially responsible for downstream 
DNA mobility in complex A. The analogue was used because it can be synthesized in large 
quantities, as required for crystallographic studies. All current evidence argues that the CPD 
analogue is structurally and functionally equivalent to the natural CPD. First, high-resolution 
small molecule crystallographic data of the CPD formacetal analogue show that it adopts the 
same structure and conformation than the normal CPD with a phosphate backbone 
(Butenandt et al, 2000; Cadet et al, 1985). Second, the base pairing properties of the lesion 
and the lesion analogue, as judged from melting point studies, are the same (Butenandt, 
1985; Taylor et al, 1990). Third, the formacetal linkage is a nearly exact bioisostere of the 
natural phosphate (Gao et al, 1992; Veal et al, 1993). Forth, the small differences, which are 
in the range of only around 0.1 Å are without significance for our results and conclusions. 
The change to the formacetal does neither affect the nucleobases nor the sugar units, the 
only difference is the missing charge of the backbone. Finally, the CPD analogue is well-
accepted as an analogue for recognition by a photolyase (Mees et al, 2004). 
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3.2.5.3 Structural similarity of lesion-containing and lesion-free elongation 
complexes. 
The RMS deviation of C  atoms between the lesion-free complete Pol II elongation complex 
(PDB code 1Y1W) and the CPD-containing complexes is 0.4 Å in all four cases. The RMS 
deviation of C  atoms between a lesion-free core Pol II elongation complex (PDB code 
1R9S) and the CPD-containing complexes is 0.9 Å in all four cases. 
3.2.5.4 Rate constants and kinetic measurements. 
The rate constant for normal elongation in vitro is greater than 20 s-1 (Edwards et al, 1991), 
too fast to be monitored by the kinetic methods used here. This is why the first incorporation 
into RNA of complex A appears to be instantaneous. 
3.2.5.5 Detection of apparently “back-stepped” complexes. 
The observed "back-stepping" in complexes B and D leads to the pre-translocated state, and 
occurs although it results in an A-C mismatch at position –8 at the upstream end of the hy-
brid. When the anomalous difference Fourier maps in complexes B and D (Figure 13C) were 
contoured at the low level of 2.5 , there were no peaks at potential bromine positions in 
neighboring nucleotides. Thus there were no significantly populated alternative states with 
different nucleic acid registers, such as non-back-stepped states. In all pre-translocated 
complexes, electron density for the 3’-terminal RNA nucleotide in position +1 was fragmented 
or absent, presumably since the phosphodiester bond between positions -1 and +1 was 
cleaved by the intrinsic 3’-exonuclease activity of Pol II under crystallization conditions (ini-
tially 50 mM magnesium ions, 10-20 days incubation time at 22ºC). 
3.2.5.6 Pol II binds the hybrid in a defined register. 
In the "back-stepped" structures B and D, the bromine peak in the template strand is ob-
served precisely at register -3, instead of -4 (Figure 12A-B, Figure 13C). This confirms that 
Pol II binds the hybrid in a defined, one base pair register, consistent with movement of Pol II 
in discrete one base pair steps (chapter 2.2.1) (Abbondanzieri et al, 2005). 
3.2.5.7 Attempts to visualize the CPD 5’-thymine-uracil mismatch crystal-
lographically. 
We included a UMP at the RNA 3’-end of complex C (Scaffold C+U, Figure 16), and re-solved 
the structure, but the resulting electron density for the UMP was fragmented (not shown). 
Soaking UTP into complex C crystals also resulted in poor density for the UMP, and did not 
result in translocation, as seen from an unaltered location of the bromine label in the DNA 
template (not shown). The modeling of the CPD thymine-uracil wobble base pair must be 
taken with care because of the limited resolution of the new data and of previous data with 
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bound nucleotide substrates. In structure D the uracil is present at position +1 but could not 
be modeled due to fragmented electron density (see chapter 3.2.5.5). 
3.2.5.8 A DNA-RNA hybrid is destabilized by a mismatch at the CPD. 
Consistent with the model that a CPD 5’-thymine-uracil mismatch destabilizes the DNA-RNA 
hybrid, the melting point of a 16 base-pair hybrid duplex with a CPD 5’-thymine-uracil mis-
match is substantially lower than that of the same duplex with a 5’-thymine-adenine base pair 
(50.1°C versus 60.0°C). The complete melting point data are as follows. Undamaged DNA-
RNA heteroduplex (5’-TT-3’): 3’-AA-5’, 63.8°C; 3’-AU-5’, 53.5°C; 3’-UA-5’, 54.0°C. Damaged 
DNA-RNA heteroduplex (5’-CPD-3’): 3’-AA-5’, 60.0°C, 3’-AU-5’, 47.5°C; 3’-UA-5’, 50.1°C. 
Thus a CPD alone only leads to a minor destabilization of the DNA-RNA duplex, consistent 
with earlier data (Butenandt, 1999). However, a T-U mismatch leads to substantial destabili-
zation. 
3.2.5.9 Additional support of lesion-bypass transcription. 
When an additional AMP is included at the RNA 3’-end of scaffold C (scaffold C+A, Figure 
16), the RNA was readily extended to the run-off transcript (Figure 17C). As a control, scaf-
fold C with an additional UMP at the RNA 3’-end was used (Scaffold C+U, Figure 16) and no 
extension of the RNA could be observed (Figure 17C). 
3.2.5.10 TFIIS induces backtracking of the CPD-stalled complex and RNA 
cleavage in discrete dinucleotide steps. 
When complex C with an additional UMP at the RNA 3’-end (scaffold C+U, Figure 16) was 
incubated with TFIIS, repeated dinucleotide cleavage from the RNA 3’-end was observed 
(Figure 17E). This indicates Pol II backtracking and movement of the CPD lesion out of the 
active site into the downstream direction. 
3.3 Specific experimental procedures 
3.3.1 Preparation of Pol II-nucleic acid complexes. 
Endogenous S. cerevisiae ten-subunit Pol II core enzyme and recombinant Rpb4/7 het-
erodimer were purified as described in chapter 4.2 and 4.4. The thymine-thymine CPD for-
macetal analogue-containing DNA oligonucleotides were synthesized as described 
(Butenandt et al, 1998). 5’-bromouracil phosphoamidite was purchased from Glen Research 
and incorporated as described by the manufacturer. Nucleic acid scaffolds (Figure 12A; 
Figure 16) were annealed by mixing equimolar amounts of synthetic template DNA, nontem-
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plate DNA, and RNA in TE buffer (chapter 4.6) at a final concentration of 100 M, heating the 
mixture to 95°C for 2 min, and slow-cooling to room temperature. Stoichiometric transcribing 
Pol II-nucleic acid complexes were assembled by incubating core Pol II for 10 min with 1.5 
molar equivalents of nucleic acid scaffold, followed by 20 min incubation with 5 molar equiva-
lents of recombinant Rpb4/7 in assembly buffer (chapter 4.6) at 20°C. The complexes were 
purified by size exclusion chromatography (Superose 6 10/300 GL) in Pol II buffer (chapter 
4.6). 
3.3.2 Crystallization and crystal treatment. 
Purified Pol II-nucleic acid complexes were concentrated to 3.5-4.5 mg/ml and an additional 
amount of the nucleic acid scaffold was added prior to crystallization to a final concentration 
of 2 M. Crystals were grown at 22 °C with the hanging drop vapor diffusion method by 
mixing 2 l of sample solution with 1 l of reservoir solution (NH4-Mg-acetate crystallization 
solution, chapter 4.7). Crystals were harvested in mother solution after 10-20 days of growth, 
when they had reached their maximum size (0.4 x 0.3 x 0.2 mm). Subsequently the crystals 
were transferred stepwise to mother solution containing additionally 0-20 % glycerol over 5 h, 
slowly cooled to 8°C, and flash-cooled by plunging into liquid nitrogen. 
3.3.3 X-ray structural analysis. 
Diffraction data were collected in 0.25° increments at the protein crystallography beamline 
X06SA of the Swiss Light Source (Table 5). Raw data were processed with Denzo and Sca-
lepack (Otwinowski & Minor, 1996). Structures were solved by molecular replacement with 
the program Phaser (McCoy et al, 2005), using the structure of the complete 12-subunit Pol 
II elongation complex without nucleic acids as a search model (PDB 1Y1W (Kettenberger et 
al, 2004)). The molecular replacement solution was subjected to rigid body refinement with 
CNS (Brunger et al, 1998). Model building was done using the program O (Jones et al, 
1991). The nucleic acids were built into the initial Fo-Fc electron density maps (Figure 13A). 
The register of the nucleic acids was unambiguously defined by bromine labeling. A thymine 
residue in the template strand was replaced for 5-bromouracil, diffraction data of the resulting 
complex were recorded at the wavelength of the bromine K absorption edge, and the result-
ing anomalous difference Fourier maps revealed single peaks demarking the positions of the 
bromine atom (Figure 13C). After minor adjustments to the protein model, atomic positions 
and B-factors were refined with CNS. Refinement was monitored carefully with the free R 
factor, calculated from the same set of excluded reflections as in refinement of complete Pol 
II (Armache et al, 2005) and the complete Pol II elongation complex (Kettenberger et al, 
2004). 
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3.3.4 Transcript extension assays. 
Stoichiometric transcribing complexes of complete Pol II, containing the 10-subunit core and 
Rpb4/7, were assembled and purified as described above, but in transcription buffer (chapter 
4.6). Full-length yeast TFIIS was purified as described in chapter 4.5. Transcribing com-
plexes of ten-subunit core Pol II were assembled by incubating core Pol II for 20 min with 
1.5-2 molar equivalents of the respective nucleic acid scaffold in transcription buffer at 20°C. 
Core Pol II elongation complexes were used for measurements presented in Figure 14E and 
Figure 17C-D. In these assays, core Pol II is generally indistinguishable from the complete 
Pol II. For all other measurements, stoichiometric elongation complexes of complete Pol II 
were used. The RNAs used for extension assays were identical to the ones used for struc-
tural studies, except five additional nucleotides (5’-UGCAU-3’) and a fluoresceine label at 
their 5’-end. For the transcript extension and cleavage reactions, 0.2-0.4 M of Pol II-nucleic 
acid complex were incubated with NTPs or TFIIS, respectively, at 28°C in transcription 
buffer. The reaction was stopped by adding 50 mM EDTA pH 7.4. Complexes were disas-
sembled and protein was denatured by gradually heating to 95 °C in 12 min and then incu-
bating at 95 °C for 4 min. After removal of protein by centrifugation, the nucleic acid samples 
were desalted using C18 ZipTips (Millipore). Fluoresceine-labeled RNA extension products 
were analyzed using a Beckmann Coulter PACE-MDQ DNA system with laser-induced fluo-
rescence detection (excitation and detection wavelengths were 488 nm and 520 nm, respec-
tively). Separations were carried out using fused silica capillaries filled with polyacrylamide 
gel (Beckmann Coulter) and Tris borate buffer (0.1 M Tris borate, 1 mM EDTA, 7 M urea, pH 
8.4). Samples were injected by a voltage pulse (10 kV for 10 s) and separated at 8 kV for 50 
min. The nucleic acids of the transcript extension reactions were additionally analyzed by 
mass spectrometry using a Bruker Daltonics autoflex 2 MALDI-TOF spectrometer. This 
confirmed the identity of the RNA extension products. 
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4 Common experimental procedures 
4.1 Measurement of protein concentration 
For the determination of protein concentrations the Bradford protein assay was used 
(Bradford, 1976). Dye reagent was purchased from Biorad and the assay was performed 
according to the manufacturer's instructions. For each new batch of dye reagent a calibration 
curve was generated using Bovine serum albumin (Fraktion V, Roth). 
4.2 Isolation of 10-subunit core Pol II from yeast 
4.2.1 Yeast fermentation 
Core RNA polymerase II was isolated from the Saccharomyces cerevisiae strain 
CB010 Rpb4 (MATa pep4::HIS3/prb1::LEU2, prc1::HISG, can1, ade2, trp1) (Edwards et al, 
1990; Fu et al, 1999). This strain carries knockouts of several cellular proteases and of 
RPB4. In the absence of Rpb4, Rpb7 dissociates from core Pol II during purification, giving 
rise to homogeneous 10-subunit core Pol II. Two types of fermenters were available for 
producing up to 1.5 kg of yeast pellet per batch. The small fermenter (ISF200, Infors) has a 
nominal volume of 20 l and is ideally run with up to 15 l of media. The large fermenter 
(ABEC, Infors) has a nominal volume of 200 l and can be filled with up to 160 l of media. 
Table 6 shows the media composition and the culture parameters of both fermenters: 
Table 6: Conditions for the fermentation of yeast 
 small fermenter (20 l) large fermenter (200 l) 
YPD media 300 g peptone 3200 g peptone 
 300 g glucose 3200 g glucose 
 222 g yeast extract 2370 g yeast extract 
 15 l desalted water 160 l desalted water 
Antibiotics1 0.75 g ampicillin 8.0 g ampicillin 
 0.15 g tetracycline⋅HCl 1.6 g tetracycline⋅HCl 
typical inoculate volume 0.3 l @ OD600  2  4-5 l @ OD600  2 
air flow 8 l/min 20 l/min 
stirrer speed 800 rpm 200 rpm 
typical growth time 12 – 15 hours 12 – 15 hours 
1added after sterilization, prior to inoculation 
4 Common experimental procedures 54
4.2.2 Purification of 10-subunit core RNA Pol II 
4.2.2.1 Buffers 
100 x protease inhibitor mix (p.i.) 
1.42 mg Leupeptin 
6.85 mg Pepstatin A 
850 mg PMSF 
1650 mg benzamidine 
dry ethanol to 50 ml 
stored at –20 °C; added immediately before use 
3x freezing buffer 
150 mM Tris-Cl, pH 7.9 @ 4 °C 
3 mM EDTA 
30 % glycerol 
30 μM ZnCl2 
3 % DMSO 
30 mM DTT 
3 x protease inhibitor mix 
1 x HSB150 buffer 
50 mM Tris-Cl, pH 7.9 @ 4 °C 
150 mM KCl 
1 mM EDTA 
10 % glycerol 
10 μM ZnCl2 
10 mM DTT 
1 x protease inhibitor mix 
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1 x HSB600 buffer 
50 mM Tris-Cl, pH 7.9 @ 4 °C 
600 mM KCl 
1 mM EDTA 
10 % glycerol 
10 μM ZnCl2 
10 mM DTT 
1 x protease inhibitor mix 
TEZ buffer 
50 mM Tris-Cl, pH 7.5 @ 20 °C 
1 mM EDTA 
10 μM ZnCl2 
1 mM DTT 
1 x protease inhibitor mix 
UnoQ buffer 
50 mM Tris-Cl, pH 7.5 @ 20 °C 
1 mM EDTA 
10 μM ZnCl2 
10 % (v/v) glycerol 
10 mM DTT 
no protease inhibitors 
1 x Pol II buffer 
5 mM Hepes pH 7.25 @ 20 °C 
40 mM ammonium sulfate 
10 μM ZnCl2 
10 mM DTT 
 
Acetate buffer 
100 mM sodium acetate pH 4.0 
500 mM sodium chloride 
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PBS 
4.3 mM Na2HPO4 
1.4 mM KH2PO4 
137 mM sodium chloride 
2.7 mM potassium chloride 
pH 7.4 
Coupling buffer 
100 mM sodium bicarbonate pH 8.3 
500 mM sodium chloride 
4.2.2.2 Harvesting and storage of yeast 
Yeast was harvested at late logarithmic/early stationary phase, monitored by OD600 meas-
urement. Cells were pelleted by centrifugation for 20 min. at 5000 rpm in a SLC6000 rotor 
(small fermenter) or by a continuous flow centrifuge (Padberg Z4IG, 20000 rpm) in case of 
the large fermenter. The cell pellet was resuspended in 330 ml of 3x freezing buffer per kg 
cells and stirred at 4 °C for 30 min, before shock-freezing in liquid nitrogen and stored at -80 
°C. 
4.2.2.3 Purification - day 1 (lysis and heparin column) 
For three bead-beaters (BioSpec), up to 600 ml of cell suspension were thawed in warm 
water. Each bead-beater was filled with 200 ml of borosilicate glass beads (0.45-0.50 mm 
diameter), 1 ml of protease inhibitor mix and 200 ml of the cell suspension. HSB150 was 
added to fill the bead-beater completely, taking care to avoid any remaining air bubbles. 
Lysis was achieved within 60-75 min of bead-beating (30 s on/90 s off) while the beater 
chambers were submersed in a salt/ice mixture. 
Glass beads were removed by filtration through a mesh funnel. The beads were washed with 
HSB150 until the flowthrough was clear. The lysate was cleared by two rounds of centrifuga-
tion (45 min at 9000 rpm in a GS3 rotor or 30 min at 12000 rpm in a SLA1500 rotor). Lipids 
were then removed by filtration of the supernatant through two layers of paper filter discs 
underneath a dressing cloth. 
The cleared lysate was applied onto a column packed with 250 ml of Heparin Sepharose 6 
FF (GE Healthcare) (flow rate: 6-8 ml/min), pre-equilibrated with 750 ml of HSB150. Elution 
was accomplished with 500 ml of HSB600 (flow rate: 6-8 ml/min). Proteins in the eluate were 
precipitated by adding 291 g of fine-ground ammonium sulfate per litre of eluate (= 50 % 
saturation), followed by 60 min of stirring at 4 °C, over-night incubation at 4 °C and finally 
centrifugation (45 min. at 12000 rpm in a SLA1500 rotor). The heparin column was restored 
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by washing with 1 l of 6 M urea, followed by water, and stored in 5 mM potassium acetate 
and 20 % (v/v) ethanol. Every five runs, the heparin column was regenerated by a brief wash 
with 500 ml of 0.1 M NaOH, followed by water and 5 mM potassium acetate in 20 % (v/v) 
ethanol. 
4.2.2.4 Purification - day 2 (immunoaffinity column) 
The ammonium sulfate pellet of day 1 was dissolved in 50 ml of buffer TEZ. More TEZ was 
added to adjust the conductivity below the conductivity of TEZ containing additionally 400 
mM ammonium sulfate (TEZ400). This sample was centrifuged (15 min at 14000 rpm in a 
SLA1500 rotor) to remove undissolved constituents and then loaded by gravity flow onto the 
immunoaffinity column at 4 °C (see chapter 4.2.2.6, flow rate: 0.5-1.0 ml/min). The column 
was pre-equilibrated with 20 ml of TEZ containing 250 mM ammonium sulfate (TEZ250). The 
flowthrough was loaded onto a second column to increase the yield of Pol II. The columns 
were brought to room temperature, washed with 25 ml of TEZ500 at room temperature and 
Pol II was eluted in 1 ml fractions with TEZ500 containing additionally 50 % (v/v) glycerol (ca. 
15 ml). Directly afterwards, 9 mM DTT was added to the elution fractions containing Pol II 
(monitored with the Bradford assay), and they were stored at 4 °C over night. The columns 
were washed with 5 ml of TEZ500 containing 70 % (v/v) ethylene glycol but no DTT, and re-
equilibrated with 25 ml of TEZ250 containing 0.02 % sodium azide. Generally, the recovery 
of Pol II decreased with each use of the column starting already from the first use. One 
reason is probably the sensitivity of the antibody towards DTT. However, it was reported 
before that these kind of columns could be used > 10 times before recovery drops (Ketten-
berger, 2005). 
4.2.2.5 Purification - day 3 (anion exchange chromatography or buffer ex-
change) 
Peak fractions from day 2 were diluted six-fold and loaded onto a UnoQ column (BioRad, 
column volume 1.35 ml), pre-equilibrated with buffer UnoQ containing 60 mM ammonium 
sulfate (UnoQ-A). The column was washed with 3 column volumes of this buffer, and Pol II 
was eluted with a linear gradient over 10 column volumes from 0-50 % buffer UnoQ contain-
ing 1 M ammonium sulfate (UnoQ-B). Pol II elutes at about 25 % buffer UnoQ-B. The column 
was restored by washing with 5 column volumes of UnoQ-B. 
To increase the final yield of Pol II the anion exchange step was replaced by a simple buffer 
exchange procedure, which didn't affect the suitability of the purified Pol II for structural or 
functional experiments. The buffer in the antibody column elution fractions was exchanged 
for 1x Pol II buffer using centrifugal ultrafiltration devices (MWCO 100,000 Da, Millipore 
Amicon Ultra-15). Completeness of the buffer exchange was monitored by measuring the 
conductivity of the flowthrough. Finally, Pol II was concentrated to 1-2 mg/ml. 
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The Pol II sample after anion exchange chromatography or after buffer exchange was split 
into aliquots of 100-500 μg Pol II. The aliquots after anion exchange chromatography were 
mixed with an equal volume of ammonium sulfate solution saturated at room-temperature, 
the aliquots in 1 x Pol II buffer with 1.13 times the volume. The mixture was incubated for > 1 
hour at 4 °C and centrifuged for 45 min. at 4 °C in a table-top centrifuge at 13000 rpm. Most 
of the supernatant was decanted so that the pellet was still covered with supernatant, before 
it was shock-frozen in liquid nitrogen and stored at –80 °C. Pol II stored this way is stable for 
about 3 months. From 600 g yeast pellet, a yield of 0.5-4 mg of highly purified Pol II was 
achieved, although higher yields up to 8 mg have been described (Kettenberger, 2005).  
4.2.2.6 Preparation of Pol II immunoaffinity resin 
The monoclonal antibody 8WG16 (NeoClone, Madison/USA), described in (Thompson & 
Burgess, 1996) is specific for the unphosphorylated CTD of Pol II and optimized to release 
Pol II upon treatment with glycerol or ethylene glycol at room temperature (“polyol responsive 
antibody“). The antibodies were purified from mouse ascites and immobilized on activated 
chromatography media according to the following procedure: 
Lyophilized ascites was dissolved in PBS to its original volume and filtered through 0.2 m 
membrane filters. The solution was passed > 3 times through a protein-A sepharose column 
(5 ml column volume, Sigma), pre-equilibrated in PBS. The column was washed with 50 ml 
PBS and antibodies were eluted with 20 ml of 0.75 M acetic acid. Fractions of 1 ml were 
collected into tubes containing 200 l of 2 M Hepes (pH 7.9) to neutralize the acid. Peak 
fractions were pooled and the protein-A sepharose column was regenerated by washing for 5 
min. with 1 M acetic acid, followed by PBS with 0.02 % sodium azide. 
The matrix for immunoaffinity columns was cyanogen bromide (CNBr)-activated sepharose 4 
B (Sigma), which reacts with free amines, e.g. accessible -NH2 groups on proteins. Care 
was taken to avoid other sources of free amines (e.g. Tris) and to use a sealed bottle of 
activated sepharose. For each immunoaffinity column, 5 ml of gel was prepared by suspend-
ing 1.43 g of CNBr-sepharose in several ml of 1 mM HCl in a disposable gravity-flow column. 
The suspended CNBr-sepharose was first washed with 100 ml of 1 mM HCl, then with 20 ml 
of coupling buffer. Coupling was performed with 10 mg of purified antibodies per column for 2 
hours at 20 °C or over night at 4 °C. When the coupling reaction was completed, no protein 
was detectable in the supernatant. The column was then washed with 25 ml of 1 M Tris, pH 8 
and incubated for 2 hours at room temperature or over night at 4 °C. Finally, the column was 
washed with 20 ml of coupling buffer, followed by acetate buffer and coupling buffer. Col-
umns were stored at 4 °C in TEZ60 with 0.02 % sodium azide. The columns could be used 
several times, if DTT exposure was reduced to a minimum, but in general a decrease in Pol 
II yield was observed already after the first use with further decrease after subsequent uses. 
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4.3 Purification of His-tagged RNA polymerase II 
Due to the low and unreproducible yield of Pol II and the high costs and fast decay of the 
antibody column an alternative purification procedure was established in the lab (Kireeva et 
al, 2003) (Cheung, A., Damsma, G.E., Lehmann, E., Sydow., J., personal communication). 
This procedure involves purification of Pol II from a yeast strain with a hexahistidine tag at 
the N-terminus of Rpb3, which is exploited in a Ni-affinity chromatography step. For the 
experiments described in this thesis, the protocol described in chapter 4.2.2 still had been 
used. 
4.4 Purification of the subcomplex Rpb4/7 
Buffer 1 
150 mM NaCl 
5 % (v/v) glycerol 
50 mM Tris pH 7.5 
10 mM -mercaptoethanol 
protease inhibitors (see chapter 4.5) 
Buffer 2 
50 mM Tris pH 7.5 
5 mM DTT 
1 mM EDTA 
Recombinant yeast Rpb4/7 was expressed in E. coli BL21(DE3) RIL (Stratagene) using a 
bicistronic vector (Armache, 2005; Sakurai et al, 1999). Cells were grown in 2 x 2 L of culture 
in auto-induction medium (Studier, 2005). After approx. 4 h, when OD600  0.6 was reached, 
the temperature was shifted from 30 °C to 20 °C. After 11 h, the cells were harvested by 
centrifugation (15 min at 5000 rpm in a SLC6000 rotor), resuspended in buffer 1 and lysed by 
means of a French Press. The lysate was cleared by centrifugation (30 min at 15000 rpm in 
a SS34 rotor) and applied onto a NiNTA column (Quiagen; 1 ml column volume). The column 
was washed subsequently with 3 ml of buffer 1, 3 ml buffer 1 containing additionally 10 mM 
imidazole and 3 ml of buffer 1 containing additionally 20 mM imidazole. Elution was per-
formed subsequently with 3 ml of buffer 1 containing additionally 50 mM imidazole and 3 ml 
of buffer 1 containing additionally 200 mM imidazole. Peak fractions were pooled, diluted 1:3 
with buffer 2 and applied on a ResourceQ column (GE Healthcare, 6 ml column volume), 
pre-equilibrated in buffer 2. Rpb4/7 was eluted with a linear gradient from 0-1000 mM NaCl in 
buffer 2. Peak fractions were concentrated and applied on a Superose12 10/300 GL gel 
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filtration column (GE Healthcare), pre-equilibrated in Pol II buffer (see chapter 4.2.2.1). The 
purified Rpb4/7 heterodimer was concentrated to 10 mg/ml and aliquots were stored at –80 
°C. 
4.5 Purification of elongation factor TFIIS 
Buffer A 
50 mM Hepes pH 7.5 
300 mM NaCl 
5% glycerol 
10 μM ZnCl2 
1 x protease inhibitors 
10 mM -mercaptoethanol 
10 x protease inhibitors 
3 mg/L leupeptin 
14 mg/L pepstatin A 
1.7 g/L PMSF 
3.3 g/L benzamidine 
dissolved in ethanol 
For the expression of full-length TFIIS, transformed BL21(DE3) RIL (Stratagene) cells were 
grown in LB medium, supplemented with chloramphenicol (30 mg/l) and kanamycin (30 
mg/l), to an OD600 of 0.7 and cooled down to 20 °C before expression was induced with 1 
mM IPTG, and continued over night.  
Cells from 1 l of culture were lysed by sonication in 50 ml of buffer A. The lysate was cleared 
by centrifugation (45 min, 13000 rpm, SS34 rotor) and was applied to a His Trap HP column 
(1 ml; GE Healthcare). The column was washed with buffer A containing 500 mM NaCl, and 
the protein was eluted over a total of 20 ml with a gradient of 0 mM to 500 mM imidazole in 
buffer A containing 500 mM NaCl. Peak fractions were diluted 5-fold in buffer A and loaded 
onto a Mono-S 5/5HR anion exchange column (GE Healthcare), pre-equilibrated with buffer 
A containing 100 mM NaCl. The TFIIS variant was eluted over a total of 15 column volumes 
with a gradient of 100-500 mM NaCl in buffer A. Peak fractions were pooled and subse-
quently applied onto a Superose 12 10/300GL gel filtration column (GE Healthcare), previ-
ously equilibrated in 1 x Transcription buffer (chapter 4.6). Elution fractions (2 mg/ml protein) 
were shock-frozen in liquid nitrogen and stored at –80°C. 
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4.6 Buffers for Pol II and Pol II ECs 
TE buffer 
10 mM Tris pH 7.4 
1 mM EDTA 
Assembly buffer 
50 mM Hepes pH 7.5 
40 mM (NH4)2SO4 
10 M ZnCl2 
5 % (v/v) glyerol 
10 mM DTT 
Pol II buffer 
5 mM Hepes pH 7.25 at 20 °C 
40 mM (NH4)2SO4 
10 M ZnCl2 
10 mM DTT 
Transcription buffer 
20 mM Hepes pH 7.6 
60 mM (NH4)2SO4 
8 mM MgSO4 
10 M ZnCl2 
10 % (v/v) glycerol 
10 mM DTT 
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4.7 Crystallization solutions for Pol II and Pol II ECs 
Tartrate crystallization solution 
100 mM Hepes pH 7.5 
750 -950 mM ammonium-sodium-tartrate 
5 mM TCEP 
for cryocooling additionally 22 % (v/v) glycerol 
NH4-Mg-acetate crystallization solution (= Natrix #38) 
50 mM Hepes pH 7.0 
140-200 mM ammonium-acetate 
150 mM magnesium-acetate 
3.5-5.5 % (v/v) PEG 6000 
5 mM TCEP 
for cryocooling additionally 20-22 % glycerol 
NH4-Na-acetate crystallization solution (= Natrix #38woMg) 
50 mM Hepes pH 7.0 
300 mM sodium-acetate 
150 mM magnesium-acetate 
4.0-7.0 % (v/v) PEG 6000 
5 mM TCEP 
for cryocooling additionally 20-22 % glycerol 
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5 Appendix 
5.1 Unpublished RNA polymerase II elongation complex structures 
5.1.1 Nucleic acid scaffolds 
T: 5-bromouracil 
AGCT: mismatch between template and nontemplate DNA 
TTAA: self complementary region 
Mismatch bubble scaffold 14d 
HK-RNA4:      5’-      UAU AUG CAU AAA 
                                       GAC CAG GC                        -3' 
HK-temC>G:    3’-  CCG TCA TGA TCA TTA CTG GTC CGC ATT CAT GAA CTC GAA CC-5' 
HK-DNA6:      5’-CCGGC AGT ACT AGT AAA CTA GTA TTG AAA GTA CTT GAG CTT   -3' 
Mismatch bubble scaffold KB-2 
KB-RNA2:      5’-      UAU AUG CAU AAA 
                                       GAC CAG GCG                       -3' 
HK-temC>G-Br: 3’-  CCg TCA TgA TCA TTA CTg gTC CgC ATT CAT gAA CTC gAA CC-5' 
HK-DNA6:      5’-CCggC AgT ACT AgT AAA CTA gTA TTg AAA gTA CTT gAg CTT   -3' 
Mismatch bubble scaffold KB-3 
KB-RNA1:      5’-                  AAA  
                                       GAC CAG GC                        -3' 
KB-tem3-Br:   3’-  CCg TCA TgA TCA TTA CTg gTC CgT TTT CAT gAA CTC gAA CC-5' 
HK-DNA6:      5’-CCggC AgT ACT AgT AAA CTA gTA TTg AAA gTA CTT gAg CTT   -3' 
Minimal scaffold KB-4 
KB-RNA1:        5’-                AAA  
                                       GAC CAG GC                        -3' 
HK-DNA4:        3'-                TTA CTg gTC CFg ATT CAT gAA CTC gA    -5' 
KB-ntem4:       5'-                                AAA gTA CTT gAg CT    -3' 
F: FaPy-G 
Natural bubble scaffold FB-2 
FB-RNA2:      5’-           UG CAU UUC 
                                       GAC CAG GC 
HK-temC>G-Br: 3’-  CCg TCA TgA TCA TTA CTg gTC CgC ATT CAT gAA CTC gAA CC -5' 
FB-ntem2:     5’-CCggC AgT ACT AgT AAT GAC CAG GCG TAA gTA CTT gAg CTT GG -3' 
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Minimal scaffold FB-3 
FB-3RNA:        5’-         UG CAU UUC 
                                       GAC CAG GC                        -3' 
FB-3tem:        3’-                TTA CTG GTC CGC ATT GAT GAA CTC GA    -5' 
FB-3ntem:       5’-                                TAA CTA CTT GAG CT    -3' 
Minimal scaffold FB-5 
FB-3RNA:        5’-         UG CAU UUC 
                                       GAC CAG GC                        -3' 
FB-3tem:        3’-                TTA CTG GBC CGC ATT GAT GAA CTC GA    -5' 
FB-5ntem:       5’-                                AAA CTA CTT GAG CT    -3' 
Minimal scaffold FB-7 
KB-RNA1:        5’-                AAA 
                                       GAC CAG GC                        -3' 
FB-3tem:        3’-                TTA CTG GBC CGC ATT GAT GAA CTC GA    -5' 
FB-5ntem:       5’-                                AAA CTA CTT GAG CT    -3' 
5.1.2 Crystallographic results 
Bubble scaffold 14d 
This scaffold was used for the structure of the complete 12-subunit Pol II EC structure by 
Hubert Kettenberger (Kettenberger et al, 2004). It is listed here for the purpose of compari-
son, because all other scaffold used in this work were designed based on this scaffold. 
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Mismatch bubble scaffold KB-2 
Mismatch bubble scaffold KB-2 Pol II EC 
Assembly 
Protein Pol II Rpb4 
recombinant Rpb4/7 
Crystallization 
Crystallization solution NH4-Mg-acetate crystallization solution (chapter 4.7) 
Cocrystallization 15.7 μM scaffold KB-2, 12-subunit Pol II was assembled without scaffold 
Special crystal treatment 
Soak (in final cryo solution) 2 μM bubble scaffold KB-2 
Dataset(s) fb239 
Data collection 
Detector MAR225 (SLS PX1) 
Program for integration/scaling Denzo/Scalepack 
Space group C2221 
Unit cell axes a, b, c (Å)  222.8, 393.3, 284.9 
Unit cell angles , ,  (°) 90.0, 90.0, 90.0 
Wavelength (Å) 0.91883 
Resolution (Å) 50-4.0 (4.14-4.0) 
Completeness (%) 99.8 (99.9) 
Redundancy 4.7 (4.5) 
Rsym (%) 10.5 (43.0) 
I/ I 12.3 (3.6) 
Refinement  
Program for refinement CNS version 1.1 
Type of refinement Rigid body refinement, using 1WCM as a model 
Rcryst (%) 32.8 (Rigid body refinement), 29.2 (Model map) 
Rfree (%) - 
Br peaks in anomalous Fourier ( ) 7 (-5) 
Translocation state (from Br peak) Post-translocation 
Observations • NTP site empty, no base pair at register +1 
• bases at register +2 apparently form no base pair 
local lack of electron density at register -8 
• probably there is a base pair present at register -9 
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Mismatch bubble scaffold KB-3 
Mismatch bubble scaffold KB-3 Pol II EC 
Assembly 
Protein Pol II Rpb4 
recombinantRpb4/7 
Crystallization 
Crystallization solution NH4-Mg-acetate crystallization solution (chapter 4.7) 
Cocrystallization 15.7 μM scaffold KB-3, 12-subunit Pol II was assembled without scaffold 
Special crystal treatment 
Soak (in final cryo solution) 2 μM bubble scaffold KB-3 
Dataset(s) fb222 
Data collection 
Detector MAR225 (SLS PX2) 
Program for integration/scaling Denzo/Scalepack 
Space group P21 
Unit cell axes a, b, c (Å)  223.1, 284.3, 225.0 
Unit cell angles , ,  (°) 90.0, 119.6, 90.0 
Wavelength (Å) 0.91881 
Resolution (Å) 50-4.0 (4.14-4.0) 
Completeness (%) 99.6 (98.1) 
Redundancy 3.6 (3.2) 
Rsym (%) 10.8 (44.5) 
I/ I 11.1 (2.8) 
Refinement  
Type of refinement Rigid body refinement, using 1WCM as a model 
Program for refinement CNS version 1.1 
Rcryst (%) 35.0 (Rigid body refinement), 32.6 (Model map) 
Rfree (%) - 
Br peaks in anomalous Fourier ( ) 7.5 (-4), 8.5 (-4) 
Translocation state (from Br peak) Post-translocation 
Observations NTP site empty, no base pair at register +1 
  Post-translocation state 
5 Appendix 67
 
Mismatch bubble scaffold KB-3 Pol II EC with 3'-dATP (soaked) 
Assembly 
Protein Pol II CTD Rpb4 
recombinantRpb4/7 
Nucleic acids Bubble scaffold KB-3 
Crystallization 
Crystallization solution NH4-Mg-acetate crystallization solution (chapter 4.7) 
Cocrystallization 1 μM bubble scaffold KB-3 
Special crystal treatment 
Soak (in final cryo solution) 1 μM bubble scaffold KB-3 
2 mM 3'-dATP (cordycepin) 
Dataset(s) fb41 
Data collection 
Detector MAR225 (SLS PX1) 
Program for integration/scaling HKL2000 
Space group C2221 
Unit cell axes a, b, c (Å)  220.2, 394.5, 283.8 
Unit cell angles , ,  (°) 90.0, 90.0, 90.0 
Wavelength (Å) 0.91977 
Resolution (Å) 50-4.0 (4.14-4.0) 
Completeness (%) 98.9 (93.1) 
Redundancy 4.6 (3.4) 
Rsym (%) 11.5 (38.9) 
I/ I 11.8 (2.3) 
Refinement  
Type of refinement Rigid body refinement, using 1WCM as a model 
Program for refinement CNS version 1.1 
Rcryst (%) 30.4 (Rigid body refinement) 
Rfree (%) - 
Translocation state (from Br peak) Pre-translocation/back-tracked 
Br peaks in anomalous Fourier ( ) 5.5 (-3) 
Observations • difference density below active center towards funnel 
• weak electron density in NTP site 
Conclusions possible scenario 1: 
• incorporation of 3'-dAMP 
• backstepping by one base pair 
• fraying/dinucleotide cleavage 
possible scenario 2: 
• incorporation of 3'-dAMP 
• translocation 
• backstepping by two base pairs 
• fraying/dinucleotide cleavage 
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Minimal scaffold KB-4 
Minimal scaffold KB-4 Pol II EC 
Assembly 
Protein Pol II CTD Rpb4 
recombinantRpb4/7 
Nucleic acids Minimal scaffold KB-4 
Crystallization 
Crystallization solution 600 mM ammonium acetate 
150 mM magnesium acetate 
50 mM HEPES, pH 7.0 
3.5-4.5 % PEG 6000 
5 mM TCEP 
Cocrystallization 1 μM bubble scaffold KB-4 
Special crystal treatment 
Soak (in final cryo solution) 2 μM bubble scaffold KB-4 
Dataset(s) fb102 
Data collection 
Detector MAR225 (SLS PX1) 
Program for integration/scaling HKL2000 
Space group C2221 
Unit cell axes a, b, c (Å)  220.8, 393.5, 282.4 
Unit cell angles , ,  (°) 90.0, 90.0, 90.0 
Wavelength (Å) 0.91947 
Resolution (Å) 50-4.0 (4.14-4.0) 
Completeness (%) 95.3 (71.2) 
Redundancy 6.5 (4.4) 
Rsym (%) 11.4 (36.0) 
I/ I 14.6 (2.8) 
Refinement  
Type of refinement Rigid body refinement, using 1WCM as a model 
Program for refinement CNS version 1.1 
Rcryst (%) 31.6 (Rigid body refinement) 
Rfree (%) - 
Br peaks in anomalous Fourier ( ) 6.0 (-3) 
Translocation state (from Br peak) Pre-translocation 
Observations • no density in NTP site 
• weak electron density for base at expected position for FaPydG (+1) 
• missing electron density for template backbone between register +1 
and +2 
Conclusions To decide, wether the EC is pre-translocated (back-stepped) because 
FaPydG cannot be accomodated at position -1, a control experiment is 
required using the same scaffold replacing FaPydG with guanine 
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Natural bubble scaffold FB-2 
Natural bubble scaffold FB-2 Pol II EC 
Assemblya 
Protein Pol II Rpb4 
recombinantRpb4/7 
Nucleic acids Natural bubble scaffold FB-7 
Crystallization 
Crystallization conditions NH4-Mg-acetate crystallization solution (chapter 4.7) 
Cocrystallization - 
Special crystal treatment 
Soak (in final cryo solution)  
Dataset(s) fb334 fb337    
Data collection 
Detector MAR225 (SLS PX1) 
Program for integration/scaling Denzo/Scalepack 
Space group C2221 C2    
Unit cell axes a, b, c (Å)  221.7 
394.6 
283.6 
222.1 
393.6 
283.2 
   
Unit cell angle  (°) 90.0 90.0    
Wavelength (Å) 0.91909 0.91901    
Resolution (Å) 50.0-4.1 
(4.25-4.10) 
50.0-4.0 
(4.14-4.10) 
   
Completeness (%) 96.6 (88.4) 99.7 (99.8)    
Redundancy 5.0 (3.6) 6.1 (5.1)    
Rsym (%) 10.5 (45.9) 11.0 (49.9)    
I/ I 11.0 (2.5) 14.4 (2.9)    
Refinement  
Type of refinement Rigid body refinement, using 1WCM as a model 
Program for refinement CNS version 1.1 
Rcryst (%) 32.3 32.1    
Rfree (%) - -    
Br peaks in anomalous Fourier ( ) - -    
Translocation state (from Br peak) ? ?    
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Natural bubble scaffold FB-2 Pol II EC 
Observations (for all datasets) 
only partial/fragmented electron density for nucleic acids 
electron density for protein is ok 
Observations for the individual datasets 
Dataset Observation 
fb334 • DNA/RNA hybrid: 
o strong electron density for bases , but not well defined 
o weak density for the backbone 
o probably different states/conformations exist 
o strongest density in Fo-Fc map: template positions -2 to -5 
• downstream DNA: fragmented electron density 
 
fb337 • DNA/RNA hybrid: 
o fragmented electron density 
o strongest density in Fo-Fc and 2Fo-Fc map: template positions -3 to -5 and RNA positions -1 to -4 
• downstream DNA: 
o fragmented electron density 
o strongest density in 2Fo-Fc map: nontemplate positions +3 to +6 
Conclusions 
The fact that that electron density for the nucleic acids of the EC was fragmented and weak on the one hand, especially for the 
backbone, and undefined on the other hand may have two causes: 
1) Low occupancy of nucleic acids 
One possible cause may be that no additional nucleic acid scaffold could not be added for cocrystallization and soaking in the 
final cryo solution (usually 1-2 μM are added). In the case of the natural bubble scaffold FB-2 assembly of the complete 
scaffold is not possible since the completely complementary nontemplate DNA would presumably displace the RNA. To 
achieve better occupancy of the nucleic acids in the EC an alternative assembly strategy might be tried: 12-subunit Pol II would 
be assembled and cocrystallized with annealed template DNA/RNA; in the final cryo solution an additional amount of annealed 
template DNA/RNA would be added before the nontemplate DNA would be soaked into the crystals to complete the ECs. 
2) Mixture of states/conformations 
The natural bubble scaffold FB-2 may not bind in a unique way, different translocational states may coexist. 
aAssembly protocol: 
Template DNA (HK-temC>G-Br) and RNA (FB-RNA2) of the natural bubble scaffold FB-2 were annealed by mixing equimolar 
amounts in TE buffer (chapter 4.6) at a final concentration of 200 M, heating the mixture to 95°C for 5 min, and slow-cooling to 
4 °C in a thermocycler. Pol II ECs were assembled by incubating core Pol II for 10 min at 20 °C with 2 molar equivalents of 
annealed template DNA/RNA, followed by 10 min incubation at 25 °C with 4 molar equivalents of nontemplate DNA (FB-ntem2) 
and then 10 min incubation at 25 °C with 5 molar equivalents of recombinant Rpb4/7 in assembly buffer (chapter 4.6). The 
complex was then purified by size exclusion chromatography (Superose 6 10/300 GL) in Pol II buffer (chapter 4.6). 
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Minimal scaffold FB-3 
Minimal scaffold FB-3 Pol II EC without/with GMPCPP and/or -amanitin 
Assembly 
Protein Pol II Rpb4 
recombinantRpb4/7 
Nucleic acids Minimal scaffold FB-3 
Crystallization 
NH4-Mg-acetate or NH4-Na-acetate crystallization solution (chapter 4.7) Crystallization conditions 
150 mM Mg-
acetate 
150 mM Mg-
acetate 
300 mM Na-
acetate 
300 mM Na-
acetate 
300 mM Na-
acetate 
Cocrystallization 2 μM bubble scaffold FB-3 
Special crystal treatment 
2 μM bubble scaffold FB-3 Soak (in final cryo solution) 
- 5 mM Mg-
acetate 
100 μM -
amanitin 
5 mM Mg-
acetate 
3 mM 
GMPCPP 
5 mM Mg-
acetate 
3 mM 
GMPCPP 
5 mM Mg-
acetate 
100 μM -
amanitin 
3 mM 
GMPCPP 
Dataset(s) fb404 fb369 fb396 fb367 fb382 
Data collection 
Detector PILATUS 6M 
(SLS PX1) 
MAR225 
(SLS PX1) 
PILATUS 6M 
(SLS PX1) 
MAR225 
(SLS PX1) 
MAR225 
(SLS PX1) 
Program for integration/scaling XDS/XSCALE with 0-dose extrapolation 
Space group C2221 C2221 C2 C2221 C2 
Unit cell axes a, b, c (Å)  223.5 
394.7 
283.5 
221.9 
392.4 
282.7 
395.1 
222.7 
284.7 
221.7 
393.0 
283.3 
393.6 
221.5 
282.2 
Unit cell angle  (°) 90.0 90.0 90.7 90.0 90.5 
Wavelength (Å) 0.91909 0.91891 0.91909 0.91909 0.91891 
Resolution (Å) 50.0-3.8 
(3.94-3.80) 
50.0-3.6 
(3.73-3.60) 
50.0-3.6 
(3.73-3.60) 
50.0-3.5 
(3.60-3.50) 
50.0-3.4 
(3.52-3.40) 
Completeness (%) 98.0 (96.7) 99.9 (100) 96.1 (98.2) 98.2 (94.5) 98.3 (90.5) 
Redundancy 2.8 (2.7) 4.3 (4.3) 1.8 (1.8) 2.6 (2.5) 2.1 (2.1) 
Rsym (%) 11.1 (46.8) 10.3 (36.2) 7.3 (43.1) 9.2 (44.3) 6.0 (32.2) 
I/ I 11.2 (3.4) 12.5 (4.3) 10.4 (2.3) 10.5 (2.4) 12.8 (2.8) 
Refinement  
Type of refinement Rigid body refinement, using 1WCM as a model 
Program for refinement CNS version 1.2 
Rcryst (%) 25.9 29.5 26.5 31.6 27.7 
Rfree (%) - - 25.6 32.5 - 
Br peaks in anomalous Fourier ( ) (as displayed by 
Coot (Emsley & Cowtan, 2004)) 
10.4 (-3) 
8.3 (-4) 
13.3 (-3) 
15.3 (-4) 
11.3 (-3/-4) 
6.6 (-3) 
6.6 (-4) 
8.5 (-3) 
9.4 (-4) 
6.5e (-3/-4) 
6.6e (-3) 
5.2e (-4) 
Translocation state (from Br peak) mixed mixed mixed mixed mixed 
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Minimal scaffold FB-3 Pol II EC without/with GMPCPP and/or -amanitin 
Observations (for all datasets) 
• Mixtures between pre- and post-translocation 
• blob between +1 and +2 template phosphate positions of 1Y1W 
• some difference density below the active site (conformational change? fraying?) 
• hybrid in > 1 conformational state (not so clear for fb369) 
• density for base in NTP-site present, more or less strong (except fb369: no density 
Observations for the individual datasets 
Dataset Soaking [Mg
2+
]/mM Observation 
fb404 only FB-3 150 • mainly pre-translocated 
• changed and weakly defined hybrid conformation 
• weak density in NTP-site 
fb369 100 M -
amanitin 
150 • mixture of pre- and post-translocated ca. 1:1 
• hybrid conformation similar to 1Y1W 
• density for amanitin and bound trigger loop 
• downstream mixture of conformations 
fb396 3 mM GMPCPP 5 • mixture of pre- and post-translocated 
• changed and weakly defined hybrid conformation 
• very weak density in NTP-site 
fb367 3 mM GMPCPP 5 • mixture of pre-and post-translocation 
• hybrid in >1 conformational state, with one state similar to 1Y1W 
• density for base in NTP-site 
• strange repetitive noise 
fb382 100 M -
amanitin + 
3 mM GMPCPP 
5 • mixture of pre- and post-translocation 
• changed and weakly defined hybrid conformation 
• weak density in NTP-site 
• density for amanitin and bound trigger loop 
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Minimal scaffold FB-5 
Minimal scaffold FB-5 Pol II EC without/with GMPCPP and/or -amanitin 
Assembly 
Protein Pol II Rpb4 
recombinant Rpb4/7 
Nucleic acids Minimal scaffold FB-5 
Crystallization 
Crystallization conditions NH4-Na-acetate crystallization solution (chapter 4.7) 
Cocrystallization 2 μM bubble scaffold FB-3 
Special crystal treatment 
2 μM bubble scaffold FB-5 Soak (in final cryo solution) 
- 5 mM Mg-
acetate 
100 μM -
amanitin 
5 mM Mg-
acetate 
100 μM -
amanitin 
5 mM Mg-
acetate 
100 μM -
amanitin 
5 mM Mg-
acetate 
100 μM -
amanitin 
15 mM 
GMPCPP 
Dataset(s) fb457 fb460 fb461 fb463 fb465 
Data collection 
Detector PILATUS 6M (SLS PX1) 
Program for integration/scaling XDS/XSCALE with 0-dose extrapolation 
Space group C2221 C2 C2 C2221 C2 
Unit cell axes a, b, c (Å)  222.7 
393.5 
283.6 
393.3 
221.8 
282.9 
393.4 
222.5 
283.6 
222.1 
394.4 
283.1 
392.9 
223.3 
283.1 
Unit cell angle  (°) 90.0 90.2 90.3 90.0 90.7 
Wavelength (Å) 0.91909 0.91909 0.91909 0.91909 0.91909 
Resolution (Å) 50.0-3.6 
(3.73-3.60) 
50.0-3.6 
(3.73-3.60) 
50.0-3.8 
(3.94-3.80) 
50.0-3.6 
(3.73-3.60) 
50.0-3.8 
(3.94-3.80) 
Completeness (%) 99.2 (100) 95.6 (92.8) 95.9 (91.8) 99.5 (99.9) 95.8 (94.8) 
Redundancy 3.8 (3.9) 1.8 (1.8) 1.8 (1.7) 3.9 (3.9) 1.8 (1.7) 
Rsym (%) 11.2 (52.2) 7.9 (55.2) 7.6 (66.2) 7.6 (54.2) 5.4 (39.1) 
I/ I 9.3 (2.7) 10.4 (1.9) 11.8 (2.3) 13.8 (2.9) 12.3 (2.5) 
Refinement 
Type of refinement Rigid body refinement, using 1WCM as a model 
Program for refinement CNS version 1.2 
Rcryst (%) 27.6 28.4 25.6 27.1 26.2 
Rfree (%) 29.1 26.9 24.8 28.7 25.2 
Br peaks in anomalous Fourier ( ) 
(as displayed by Coot (Emsley & Cowtan, 2004)) 
12.4 (-3/-4) 
 
7.2 (-3/-4) 
4.5 (-3) 
7.6 (-3) 
5.8 (-4) 
6.5 (-3) 
5.7 (-4) 
7.7 (-3/-4) 
9.1 (-3/-4) 
 
7.8 (-3) 
7.6 (-4) 
7.2 (-4) 
Translocation state (from Br peak) mixed mixed mixed mixed mixed 
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Minimal scaffold FB-5 Pol II EC without/with GMPCPP and/or -amanitin 
Observations (for all datasets) 
• Mixtures between pre- and post-translocation 
• clear mixtures for templating base between “template insertion” and “template pre-insertion” states (regardless of soaking 
!!!) 
• blob between +1 and +2 template phosphate positions of 1Y1W 
• some difference density below the active site (conformational change? fraying?) 
• hybrid in > 1 conformational state 
• no density for base in NTP-site present, which seems to be base pairing with the templating base 
Observations for the individual datasets 
Dataset Soaking [Mg
2+
]/mM Observation 
fb457 only FB-5 0 • mainly pre-translocation 
• changed and weakly defined hybrid conformation 
fb460 100 M -
amanitin 
5 • mixture of pre- and post-translocation 
• changed and weakly defined hybrid conformation 
• density for amanitin and bound trigger loop, the latter weak 
• blobs for Br in anomalous and fofc do not lie perfectly on top of each 
other 
fb461 100 M -
amanitin 
5 • mixture of pre- and post-translocation, more pre 
• changed and weakly defined hybrid conformation 
• density for amanitin and bound trigger loop, the latter weak 
fb463 100 M -
amanitin 
5 • mixture of pre- and post-translocation, more pre 
• changed and weakly defined hybrid conformation 
• density for amanitin and bound trigger loop, the latter weak 
fb465 100 M -
amanitin + 
15 mM 
GMPCPP 
5 • mixture of pre- and post-translocation (weak Br-signal) 
• changed and weakly defined hybrid conformation 
• no density in NTP-site 
• density for amanitin and bound trigger loop, the latter fragmented and 
weak 
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Minimal scaffold FB-7 
Minimal scaffold FB-7 Pol II EC without/with -amanitin 
Assembly 
Protein Pol II Rpb4 
recombinant Rpb4/7 
Nucleic acids Minimal scaffold FB-7 
Crystallization 
Crystallization conditions NH4-Na-acetate crystallization solution (chapter 4.7) 
Cocrystallization 2 μM bubble scaffold FB-7 
Special crystal treatment 
2 μM bubble scaffold FB-7 Soak (in final cryo solution) 
- 5 mM Mg-
acetate 
100 μM -
amanitin 
5 mM Mg-
acetate 
100 μM -
amanitin 
5 mM Mg-
acetate 
100 μM -
amanitin 
5 mM Mg-
acetate 
100 μM -
amanitin 
Dataset(s) fb444a fb437a fb438 fb440 fb441 
Data collection 
Detector PILATUS 6M (SLS PX1) 
Program for integration/scaling XDS/XSCALE with 0-dose extrapolation 
Space group C2221 C2221 C2 C2 C2221 
Unit cell axes a, b, c (Å)  221.9 
393.1 
283.1 
220.6 
394.2 
284.0 
394.0 
221.2 
283.6 
393.9 
222.1 
283.4 
222.6 
394.2 
283.4 
Unit cell angle  (°) 90.0 90.0 90.3 90.6 90.0 
Wavelength (Å) 0.91909 0.91909 0.91909 0.91909 0.91901 
Resolution (Å) 50.0-3.6 
(3.73-3.60) 
50.0-3.4 
(3.52-3.40) 
50.0-3.4 
(3.52-3.40) 
50.0-3.4 
(3.52-3.40) 
50.0-3.4 
(3.52-3.40) 
Completeness (%) 99.9 (99.9) 99.9 (99.9) 94.4 (96.1) 92.6 (98.0) 99.7 (99.9) 
Redundancy 3.8 (3.6) 3.6 (3.5) 1.8 (1.8) 1.8 (1.8) 3.9 (3.9) 
Rsym (%) 6.7 (36.8) 13.3 (46.7) 5.4 (41.0) 7.3 (41.7) 7.1 (52.4) 
I/ I 15.9 (3.9) 8.5 (3.0) 13.1 (2.2) 8.9 (2.3) 15.9 (3.0) 
Refinement  
Type of refinement Rigid body 
refinement, 
using 1WCM as 
a model 
Full model 
building and 
refinement 
(positional 
and individ-
ual B-factor) 
Rigid body refinement, using 1WCM as a 
model 
Program for refinement CNS version 1.2 
Rcryst (%) 26.2 25.5 27.2 28.9 27.4 
Rfree (%) - 28.8 26.0 27.2 29.4 
Br peaks in anomalous Fourier ( ) 
(for fb438, fb440, and fb441 as displayed by Coot 
(Emsley & Cowtan, 2004)) 
7.9 (-3) 
4.9 (-4) 
7.8 (-4) 
 
10.8 (-3) 
5.6 (-4) 
12.6 (-3) 
10.5 (-4) 
10.2 (-3/-4) 
6.5 (-3) 
5.0 (-3) 
8.9 (-4) 
13.8 (-3) 
15.6 (-4) 
Translocation state (from Br peak) mixed post-transl. mixed mixed mixed 
asame datasets as in Table 3 
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Minimal scaffold FB-7 Pol II EC with -amanitin and GMPCPP 
Assembly 
Protein Pol II Rpb4 
recombinant Rpb4/7 
Nucleic acids Minimal scaffold FB-7 
Crystallization 
Crystallization conditions NH4-Na-acetate crystallization solution (chapter 4.7) 
Cocrystallization 2 μM bubble scaffold FB-7 
Special crystal treatment 
2 μM bubble scaffold FB-7 Soak (in final cryo solution) 
5 mM Mg-
acetate 
100 μM -
amanitin 
3 mM 
GMPCPP 
5 mM Mg-
acetate 
3 mM 
GMPCPP 
100 μM -
amanitin 
   
Dataset(s) fb425 fb433    
Data collection 
Detector PILATUS 6M (SLS PX1) 
Program for integration/scaling XDS/XSCALE with 0-dose extrapolation 
Space group C2221 C2    
Unit cell axes a, b, c (Å)  222.3 
393.5 
283.5 
394.8 
223.1 
284.2 
   
Unit cell angle  (°) 90.0 90.3    
Wavelength (Å) 0.91908 0.91908    
Resolution (Å) 50.0-3.6 
(3.73-3.60) 
50.0-3.5 
(3.63-3.50) 
   
Completeness (%) 99.9 (100) 98.4 (98.0)    
Redundancy 3.9 (3.8) 1.7 (1.7)    
Rsym (%) 6.7 (34.2) 6.4 (2.7)    
I/ I 16.6 (4.5) 9.6 (2.8)    
Refinement  
Type of refinement Rigid body refinement, using 1WCM as a model 
Program for refinement CNS version 1.2 
Rcryst (%) 26.0 26.9    
Rfree (%) - -    
Br peaks in anomalous Fourier ( ) 
(as displayed by Coot (Emsley & Cowtan, 2004)) 
21.2 (-3/-4) 13.4 (-3) 
10.3 (-4) 
10.2 (-3) 
11.9 (-4) 
   
Translocation state (from Br peak) mixed mixed    
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Minimal scaffold FB-7 Pol II EC with -amanitin and GMPCPP 
Observations (for all datasets) 
• Mixtures between pre- and post-translocation (except FB437) 
• blob between +1 and +2 template phosphate positions of 1Y1W 
• some difference density below the active site (conformational change? fraying?) (except FB437) 
• hybrid in > 1 conformational state (except FB 437, also one state seems to be prominent for FB440) 
• mostly weak density for base in NTP-site present, which seems to be base pairing with the templating base (no density 
observed in FB440, FB441, FB437) 
• templating base mainly in “template insertion” site (mixtures apparent e.g. in FB425, FB433, FB440; FB437 is “pre-
insertion”!) 
Observations for the individual datasets 
Dataset Soaking [Mg
2+
]/mM Observation 
fb444 only FB-7 0 • mixture of pre- and post-translocation, more pre 
• changed and weakly defined hybrid conformation 
• downstream mixture of conformations 
fb437 100 M -
amanitin 
5 • post-translocation 
• template base in pre-insertion site 
• hybrid density similar to 1Y1W and well defined 
• density for amanitin and bound trigger loop 
fb438 100 M -
amanitin 
5 • mixture of pre- and post-translocation, little more pre 
• changed and weakly defined hybrid 
• conformation density for amanitin and bound trigger loop 
• part of fork loop 2 ordered 
• difference density peaks on upstream side of bridge helix 
fb440 100 M -
amanitin 
5 • mixture of pre- and post-translocation, more post 
• hybrid conformation more similar to 1Y1W 
• density for amanitin and bound trigger loop 
• part of fork loop 2 ordered 
• mixture between +1 template insertion and pre-insertion 
• difference density peaks on upstream side of bridge helix 
fb441 100 M -
amanitin 
5 • mixture of pre- and post-translocation 
• changed and weakly defined hybrid conformation density for amanitin 
and bound trigger loop 
• part of fork loop 2 ordered 
fb425 100 M -
amanitin + 
3 mM GMPCPP 
5 • mixture of pre- and post-translocation, ca. 1:1 
• changed and weakly defined hybrid conformation 
• weak density in NTP-site 
• density for amanitin and bound trigger loop 
fb433 3 mM GMPCPP 
+ 
100 M -
amanitin 
5 • mixture of pre- and post-translocation, ca. 1:1 
• changed and weakly defined hybrid conformation 
• density for amanitin and bound trigger loop 
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5.2 Attempts to improve the resolution of diffraction data from 
complete 12-subunit RNA polymerase II crystals 
5.2.1 Capillary mounting and measuring at room temperature 
To find out, whether cryo-cooling of 12-subunit Pol II EC crystals influences the crystal pa-
rameters and diffraction quality, crystals of an EC with a minimum bubble scaffold (Scaffold 
C+U, Figure 16, page 39) were measured at room temperature. Crystallization was performed 
as described in chapter 3.3.2, crystallization solution contained 170 mM ammonium acetate, 
150 mM magnesium acetate, 50 mM Hepes pH 7.0, 3.5-5.5 % PEG 6000, 5 mM TCEP (NH4-
Mg-acetate crystallization solution, see chapter 4.7) .For room temperature measurement, 
crystals were mounted in Quartz capillaries (0.5-1.0 mm diameter, Hampton research) at 
room temperature. The crystals were sucked into the capillaries, surrounding mother liquor 
was removed and a reservoir of mother liquor was placed at both ends of the capillary. Fi-
nally the capillaries were sealed with wax at both ends. To test additionally, whether adding 
the cryoprotectant glycerol changes crystal and/or diffraction properties, crystals with and 
without glycerol were measured. Four crystals were measured, for which the standard cryo-
protectant treatment was applied (0-20 % glycerol in 5 steps), except that incubation over 
night was at room temperature instead of 4 °C. Three crystals were measured without the 
cryoprotectant treatment applied, i.e. glycerol added. The capillaries containing the crystals 
were then transferred carefully in a styrofoam box to the synchrotron beamline PX1 at the 
SLS. For each crystal several 0.25 ° oscillation images with 45 ° spacing were recorded 
(room temperature, exposure time: 1 s, readout time: approx. 4 s, no filter, ring current 350 
mA, detector MAR225). 
Signs of radiation damage could in general already be observed after the first image (1 s 
exposure), in particular a reduction in the diffraction intensity at higher resolution. On the first 
image of all tested capillary-mounted crystals, the spots on the detector were particularly 
small and round-shaped, as compared to cryo-cooled crystals. However the maximum reso-
lution, estimated visually, was somewhat lower (5-8Å), but there was no significant difference 
between crystals with and without cryoprotectant treatment. Diffraction data was indexed with 
the program MOSFLM (Leslie, 2006) from the first one to three images to test whether cryo-
cooling and/or addition of glycerol have an effect on unit cell parameters (Table 7 and Table 
8). No significant change of unit cell parameters could be observed. 
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Table 7: Maximum resolution, space group and unit cell parameters of capillary-mounted Pol II EC crystals with 
cryoprotectant treatment. 
Unit cell axes Crystal # Maximum 
resolution 
Space group 
a b c 
fb310 6 C2221 223 395 285 
fb311 6 C2221 224 395 284 
fb313 5 C2221 223 395 285 
fb314 6.5 C2221 223 395 285 
Table 8: Maximum resolution, space group and unit cell parameters of capillary-mounted Pol II EC crystals 
without cryoprotectant treatment 
Unit cell axes Crystal # Maximum 
resolution 
Space group 
a b c 
fb316 8 C2221 222 405 284 
fb317 6.5 C2221 222 395 284 
fb318 7.5 C2221 223 394 284 
5.2.2 Crystallization of 12-subunit Pol II without CTD 
The CTD of Pol II was removed, using a newly introduced TEV cleavage site (Kettenberger, 
2005). The resulting 12-subunit Pol II without CTD crystallized under the same conditions as 
Pol II with CTD. The crystals were crystallographically indistinguishable from the 12-subunit 
Pol II crystals, however large crystals apparently formed slightly more readily and reproduci-
bly.  
5.2.3 Further attempts in table form 
Approach Ca Reference Observation/Conclusion 
New crystallization condi-
tions: 300 mM Na-acetate 
(NH4-Na-acetate crystalliza-
tion solution, chapter 4.7) 
replace 150 mM Mg-acetate 
(NH4-Mg-acetate crystalliza-
tion solution, chapter) 
3 - Pol II EC apparently crystal-
lizes more readily and repro-
ducibly to form large three-
dimensional crystals, from 
which apparently diffraction 
data to slightly higher resolu-
tion can be collected. 
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Approach Ca Reference Observation/Conclusion 
Crosslinking with glutaral-
dehyde before cryoprotec-
tant treatment 
1,2 (Lusty, 1999) crystals became prone to 
dissolving in pure water; no 
significant change of diffrac-
tion properties 
Using oils (Paraffin oil, 
PFO) as cryoprotectants: 
removal of adhering mother 
liquor from crystal by drag-
ging through the oil. 
1,3 - no improvement of diffraction 
properties 
Removal of the cold gas 
layer above liquid nitrogen 
for by blowing with a dry 
nitrogen gas stream for 
cryo-cooling by plunging 
into liquid nitrogen 
1,2,3 (Warkentin et al, 2006) no significant change of 
diffraction properties 
Cryo-cooling by plunging 
into liquid Ethane 
2,3 - no significant change of 
diffraction properties 
Crystal annealing by simply 
blocking the cryostream 
 (Heras & Martin, 2005) 
and references therein 
diffraction lost completely 
Crystal annealing by block-
ing the cryostream, transfer-
ring the crystal back to the 
mother liquor, incubating 
several minutes in the 
mother liquor and re-cooling 
in the cryostream 
 (Heras & Martin, 2005) 
and references therein 
diffraction intensity and 
maximum resolution signifi-
cantly lowered, but diffraction 
is not completely lost 
New pixel detector PILA-
TUS 6M 
1,2,3 (Broennimann et al, 
2006) 
 
XDS/XSCALE with 0-dose 
extrapolation for indexing, 
integration/scaling instead 
of DENZO/SCALEPACK 
1,2,3 (Kabsch, 1993) 
(Diederichs et al, 
2003) 
better data statistics, using 0-
dose extrapolation 
CNS version 1.2 instead of 
CNS version 1.1 for struc-
ture  refinement and map 
calculation 
1,2,3 (Brunger, 2007) Improved bulk solvent correc-
tion with parameter grid 
search improves R-factor 
aCrystallization solution used for crystallization and during crystal treatment: (1) Tartrate (2) NH4-Mg-acetate (3) NH4-Na-
acetate crystallization solution (see chapter 4.7) 
5.2.4 Ideas for the future 
• Screen for new crystal form of 12-subunit Pol II without CTD 
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• Screen for new crystal form of 12-subunit Pol II EC using Pol II without CTD and/or 
nucleic acid scaffolds forming crystal contacts 
• Controlled dehydration of 12-subunit Pol II crystals using the free mounting system 
(Kiefersauer et al, 2000). 
• Try radioprotectants to reduce radiation damage during data collection (Kauffmann et 
al, 2006; Southworth-Davies & Garman, 2007) 
• Structure refinement with TLS for improving R-factor and electron density maps (Re-
fmac, phenix.refine) 
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6 Conclusions and Outlook 
Results presented in chapter 2 of this thesis have led to a more detailed mechanistic under-
standing of translocation by RNA polymerase II. Together with the other crystallographic 
snapshots of the nucleotide addition cycle, a movie of elongating Pol II can now be assem-
bled. Further insights into the coupling of catalysis and translocation could be obtained by 
trapping the EC right after catalysis but before the release of pyrophosphate, and structurally 
analyzing the resulting product complex. 
The studies, described in chapter 3 of this thesis unveiled distinct molecular recognition 
mechanisms of transcribing Pol II for two different bulky DNA lesions. Because of the appar-
ent absence of a general lesion recognition mechanism, the effect of other kinds of DNA 
lesions on transcribing Pol II will have to be examined individually. This also includes lesions, 
which can be bypassed by Pol II but may cause transcriptional mutagenesis, like some oxi-
dative lesions. 
In the absence of a DNA lesion, mismatch nucleotide incorporation and extension of the 
mismatch lead to transcriptional mutagenesis, affecting the fidelity of gene transcription. For 
a more comprehensive understanding of transcriptional fidelity, it is necessary to survey the 
events causing errors in the mRNA and analyze the mechanisms preventing them. 
Many more questions on Pol II elongation remain unanswered. Structural and biochemical 
characterization of functional Pol II ECs can provide extremely valuable and detailed informa-
tion on the mechanism of transcription, but it is a formidable challenge because of the large 
size and transient nature of these complexes. Further investigation of Pol II could focus on 
more natural elongation complexes with a fully complementary nontemplate strand, com-
plexes with additional protein factors involved in transcription, and complexes of Pol II with 
natural RNA inhibitors, to name just a few. 
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7 Abbreviations 
AMP adenosine monophosphate 
ATP adenosine triphosphate 
CMP cytosine monophosphate 
CPD cyclobutane pyrimidine dimer 
CTD C-terminal domain of Rpb1 of Pol II 
CTP cytosine triphosphate 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
DPE downstream promoter element 
DTT dithiothreitol 
E.coli Escherichia coli 
EC elongation complex 
EDTA ethylene diamine tetraacetic acid 
EM electron microscopy 
GMP guanosine monophosphate 
GMPCPP Guanosine-5’-[( , )-methyleno]triphosphate 
GTF general transcription factor 
GTP guanosine triphosphate 
Hepes 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
INR initiator element 
IPTG isopropyl -D-1-thiogalactopyranoside 
MALDI-TOF matrix-assisted laser desorption ionization with time-of-flight analysator 
mass spectrometry 
mRNA messenger RNA 
MWCO molecular weight cutoff 
NAC nucleotide addition cycle 
NER nucleotide excision repair 
NTP nucleotide triphosphate 
PDB protein data bank 
PEG polyethylene glycol (number indicates average molecular weight in Da) 
PFO perfluoropolyether 
PIC preinitiation complex 
Pol eukaryotic DNA-dependent RNA polymerase 
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RMSD root mean square deviation 
RNA ribonucleic acid 
RNAP DNA-dependent RNA polymerase 
Rpb subunit of Pol II (=RNA polymerase B) 
S.cerevisiae Saccharomyces cerevisiae 
TAF TBP-associated factor 
Taq Thermus aquaticus 
TBP TATA binding protein 
TCEP tris(2-carboxyethyl)phosphine 
TCR transcription coupled repair 
TFII transcription factor of Pol II transcription 
Tris trishydroxymethylaminomethane 
Tth Thermus thermophilus 
UMP uridine monophosphate 
UTP uridine triphosphate 
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